US20050287630A1
(en)
*
|
1995-04-27 |
2005-12-29 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
KR100654645B1
(en)
*
|
1995-04-27 |
2007-04-04 |
아브게닉스, 인크. |
Human Antibodies from Immunized Genomous
|
US20050241006A1
(en)
*
|
1995-04-27 |
2005-10-27 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US6235883B1
(en)
*
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US20020173629A1
(en)
*
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6358508B1
(en)
*
|
1997-06-11 |
2002-03-19 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor TR9
|
US6417168B1
(en)
*
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
US7067144B2
(en)
*
|
1998-10-20 |
2006-06-27 |
Omeros Corporation |
Compositions and methods for systemic inhibition of cartilage degradation
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
RS51309B
(en)
*
|
1998-12-23 |
2010-12-31 |
Pfizer Inc. |
Human monoclonal antibodies to ctla-4
|
EP1161451A4
(en)
|
1999-02-26 |
2006-05-17 |
Human Genome Sciences Inc |
Human endokine alpha and methods of use
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
JP2003520195A
(en)
*
|
1999-05-14 |
2003-07-02 |
イムクローン システムズ インコーポレイティド |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
EP2112167A3
(en)
|
1999-06-25 |
2010-12-22 |
Genentech, Inc. |
Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies
|
CN1371416B
(en)
|
1999-08-24 |
2012-10-10 |
梅达里克斯公司 |
Human CTLA-4 antibodies and their uses
|
GB0002952D0
(en)
*
|
2000-02-09 |
2000-03-29 |
Pharma Mar Sa |
Process for producing kahalalide F compounds
|
EP2332579A3
(en)
|
2000-02-10 |
2011-09-21 |
Abbott Laboratories |
Antibodies that bind human interleukin-18 and methods of making and using
|
CA2405709A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
PT2281843T
(en)
|
2000-06-16 |
2017-01-02 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(en)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
JP2004527456A
(en)
*
|
2000-08-09 |
2004-09-09 |
イムクローン システムズ インコーポレイティド |
Treatment of hyperproliferative diseases with EGF receptor antagonists
|
EP2338512A1
(en)
|
2000-11-28 |
2011-06-29 |
MedImmune, LLC |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
WO2002053596A2
(en)
|
2001-01-05 |
2002-07-11 |
Pfizer Inc. |
Antibodies to insulin-like growth factor i receptor
|
CN1564826A
(en)
|
2001-02-09 |
2005-01-12 |
人类基因组科学公司 |
Human G-protein chemokine receptor (CCR5) HDGNR10
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
KR20030093316A
(en)
|
2001-04-13 |
2003-12-06 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
Vascular endothelial growth factor 2
|
ATE446317T1
(en)
|
2001-05-11 |
2009-11-15 |
Ludwig Inst For Cancer Res Ltd |
SPECIFIC BINDING PROTEINS AND THEIR USE
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
WO2002092017A2
(en)
|
2001-05-16 |
2002-11-21 |
Albert Einstein College Of Medicine Of Yeshiva University |
Human antipneumococcal antibodies from non-human animals
|
US7595378B2
(en)
*
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
CN1966525A
(en)
*
|
2001-06-13 |
2007-05-23 |
根马布股份公司 |
Human monoclonal antibodies to epidermal growth factor receptor (egfr)
|
AR039067A1
(en)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
ANTIBODIES FOR CD40
|
WO2003052082A2
(en)
*
|
2001-12-18 |
2003-06-26 |
Whitehead Institute For Biomedical Research |
Fusion partner cells and uses thereof
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20080063639A1
(en)
*
|
2002-01-18 |
2008-03-13 |
Pierre Fabre Medicament |
Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
|
US7241444B2
(en)
*
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
US20080193445A1
(en)
*
|
2002-01-18 |
2008-08-14 |
Liliane Goetsch |
Novel anti-IGF-IR antibodies and uses thereof
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
MXPA04009381A
(en)
|
2002-03-27 |
2005-01-25 |
Immunex Corp |
Methods for increasing polypeptide production.
|
ATE435239T1
(en)
|
2002-03-29 |
2009-07-15 |
Schering Corp |
HUMAN MONOCLONAL ANTIBODIES TO INTERLEUKIN-5 AND THESE COMPREHENSIVE METHODS AND COMPOSITIONS
|
EP1499352A4
(en)
|
2002-04-12 |
2006-10-11 |
Medimmune Inc |
Recombinant anti-interleukin-9 antibodies
|
US20040033543A1
(en)
*
|
2002-05-20 |
2004-02-19 |
Gisela Schwab |
Treatment of renal carcinoma using antibodies against the EGFr
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US20040022792A1
(en)
*
|
2002-06-17 |
2004-02-05 |
Ralph Klinke |
Method of stabilizing proteins at low pH
|
US20040132097A1
(en)
*
|
2002-06-19 |
2004-07-08 |
Bacus Sarah S. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
MXPA05000403A
(en)
|
2002-07-15 |
2005-07-22 |
Genentech Inc |
METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES.
|
US7425620B2
(en)
|
2002-08-14 |
2008-09-16 |
Scott Koenig |
FcγRIIB-specific antibodies and methods of use thereof
|
CN101987871A
(en)
|
2002-09-27 |
2011-03-23 |
赞科股份有限公司 |
Optimized fc variants and methods for their generation
|
EP2891666B1
(en)
|
2002-10-16 |
2017-06-28 |
Purdue Pharma L.P. |
Antibodies that bind cell-associated CA 125/O722P and methods of use thereof
|
GB0304367D0
(en)
*
|
2003-02-26 |
2003-04-02 |
Pharma Mar Sau |
Methods for treating psoriasis
|
EP1565478B1
(en)
*
|
2002-11-12 |
2017-08-02 |
The Brigham And Women's Hospital, Inc. |
Polysaccharide vaccine for staphylococcal infections
|
US20040147428A1
(en)
*
|
2002-11-15 |
2004-07-29 |
Pluenneke John D. |
Methods of treatment using an inhibitor of epidermal growth factor receptor
|
WO2004052184A2
(en)
*
|
2002-12-12 |
2004-06-24 |
Oncotech, Inc. |
Genes related to sensitivity and resistance to chemotherapeutic drug treatment
|
JP4898120B2
(en)
|
2002-12-20 |
2012-03-14 |
アボット バイオセラピューティクス コーポレイション |
Antibodies against GPR64 and methods of use thereof
|
WO2004063351A2
(en)
|
2003-01-09 |
2004-07-29 |
Macrogenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
DE10303974A1
(en)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid β (1-42) oligomers, process for their preparation and their use
|
US20080014594A1
(en)
*
|
2003-01-31 |
2008-01-17 |
Kevin Hestir |
Lung-Expressed Polypeptides
|
DE602004027888D1
(en)
|
2003-02-20 |
2010-08-12 |
Seattle Genetics Inc |
ANTI-CD70 ANTIBODY MEDICAMENT CONJUGATES AND THEIR
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
NZ607886A
(en)
|
2003-03-19 |
2014-09-26 |
Biogen Idec Inc |
Nogo receptor binding protein
|
JP4764818B2
(en)
|
2003-04-11 |
2011-09-07 |
メディミューン,エルエルシー |
Recombinant IL-9 antibody and use thereof
|
JP2007525172A
(en)
*
|
2003-04-14 |
2007-09-06 |
ボード オブ リージェンツ ザ ユニバーティー オブ テキサス システム |
Methods for ex vivo production of polyclonal and monoclonal antibodies without hybridomas and methods for producing immortalized cell populations
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
US20070036795A1
(en)
|
2003-06-09 |
2007-02-15 |
Samuel Waksal |
Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist
|
KR20130065723A
(en)
*
|
2003-06-27 |
2013-06-19 |
암젠 프레몬트 인코포레이티드 |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
AU2004259727A1
(en)
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of cancer and infectious diseases.
|
US20050221383A1
(en)
|
2003-08-08 |
2005-10-06 |
Choong-Chin Liew |
Osteoarthritis biomarkers and uses thereof
|
GB0321066D0
(en)
*
|
2003-09-09 |
2003-10-08 |
Pharma Mar Sau |
New antitumoral compounds
|
AR045563A1
(en)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
ANTIBODIES DIRECTED TO M-CSF
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
KR101438983B1
(en)
|
2003-11-06 |
2014-09-05 |
시애틀 지네틱스, 인크. |
Monomethylvaline compounds capable of conjugation to ligands
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
US7371381B2
(en)
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
ES2533084T3
(en)
|
2003-12-23 |
2015-04-07 |
Genentech, Inc. |
Cancer treatment with novel anti-IL 13 monoclonal antibodies
|
US20100190150A1
(en)
*
|
2004-01-07 |
2010-07-29 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
DK2177537T3
(en)
|
2004-01-09 |
2011-12-12 |
Pfizer |
Antibodies to MAdCAM
|
ES2383306T3
(en)
|
2004-02-03 |
2012-06-20 |
The Regents Of The University Of Michigan |
Compositions for the treatment of breast and pancreas cancer
|
PL1729795T3
(en)
|
2004-02-09 |
2016-08-31 |
Human Genome Sciences Inc |
Albumin fusion proteins
|
TW200533339A
(en)
*
|
2004-03-16 |
2005-10-16 |
Bristol Myers Squibb Co |
Therapeutic synergy of anti-cancer compounds
|
CA2560305C
(en)
*
|
2004-03-19 |
2016-07-05 |
Imclone Systems Incorporated |
Human anti-epidermal growth factor receptor antibody
|
US7625549B2
(en)
*
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
CN1961003B
(en)
|
2004-03-31 |
2013-03-27 |
健泰科生物技术公司 |
Humanized anti-TGF-beta antibodies
|
EP1737489B1
(en)
|
2004-04-08 |
2012-01-11 |
David B Agus |
ErbB2 antagonists for tumor pain therapy
|
DK1745075T3
(en)
|
2004-04-21 |
2013-06-24 |
Brigham & Womens Hospital |
POLY-N-ACETYLGLUCOSAMINE (PNAG / DPNAG) BINDING PEPTIDES AND PROCEDURES FOR USING IT
|
KR20120133403A
(en)
|
2004-06-01 |
2012-12-10 |
도만티스 리미티드 |
Bispecific fusion antibodies with enhanced serum half-life
|
BRPI0511776B1
(en)
|
2004-06-01 |
2016-11-29 |
Sinai School Medicine |
genetically engineered swine influenza attenuated virus, immunogenic formulation, pharmaceutical formulation, use of the immunogenic formulation, use of genetically engineered swine influenza attenuated virus, use of the pharmaceutical formulation and method for producing a vaccine, an immunogenic formulation or a pharmaceutical formulation
|
AU2005249490B2
(en)
|
2004-06-01 |
2010-07-29 |
Genentech, Inc. |
Antibody drug conjugates and methods
|
BRPI0512500A
(en)
|
2004-06-24 |
2008-03-11 |
Biogen Idec Inc |
treatment or conditions involving demyelination
|
AU2005272993B2
(en)
|
2004-07-15 |
2010-02-11 |
Xencor, Inc |
Optimized Fc variants
|
EP2322215A3
(en)
|
2004-07-16 |
2011-09-28 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
|
JP5060293B2
(en)
|
2004-08-03 |
2012-10-31 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
TAJ in neural function
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
CA2577423C
(en)
|
2004-08-16 |
2012-11-06 |
Quark Biotech, Inc. |
Therapeutic uses of inhibitors of rtp801
|
AU2004224925C1
(en)
|
2004-08-30 |
2011-07-21 |
Biotest Ag |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
US7700720B2
(en)
|
2004-09-21 |
2010-04-20 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
PL1791565T3
(en)
|
2004-09-23 |
2016-10-31 |
|
Cysteine engineered antibodies and conjugates
|
JO3000B1
(en)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
Antibody Formulations.
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
DK2325207T3
(en)
|
2004-11-12 |
2017-06-06 |
Xencor Inc |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
US20090214534A1
(en)
|
2004-12-02 |
2009-08-27 |
Steve Holmes |
Bispecific Domain Antibodies Targeting Serum Albumin And GLP-1 Or PYY
|
PE20060777A1
(en)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
|
CN101141981A
(en)
|
2005-01-21 |
2008-03-12 |
健泰科生物技术公司 |
Fixed dosing of her antibodies
|
CA2599589A1
(en)
|
2005-02-07 |
2006-08-17 |
Genenews,Inc. |
Mild osteoarthritis biomarkers and uses thereof
|
DK1853718T3
(en)
|
2005-02-15 |
2015-11-09 |
Univ Duke |
ANTI-CD19 ANTIBODIES AND THEIR USE IN ONCOLOGY
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
US20090155247A1
(en)
*
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
EP2399605A1
(en)
|
2005-02-23 |
2011-12-28 |
Genentech, Inc. |
Extending time to disease progression or survival in cancer patients
|
JP2008531730A
(en)
|
2005-03-04 |
2008-08-14 |
キュアーディーエム、インク. |
Methods and pharmaceutical compositions for treating type I diabetes mellitus and other conditions
|
MX2007010971A
(en)
|
2005-03-08 |
2007-09-19 |
Pharmacia & Upjohn Co Llc |
Anti-ctla-4 antibody compositions.
|
US20060216288A1
(en)
*
|
2005-03-22 |
2006-09-28 |
Amgen Inc |
Combinations for the treatment of cancer
|
WO2006113665A2
(en)
|
2005-04-15 |
2006-10-26 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
KR100680141B1
(en)
*
|
2005-04-20 |
2007-02-07 |
주식회사 녹십자 |
- monoclonal antibody against epidermal growth factor receptor and hybridoma cell line producing the same
|
US7807159B2
(en)
|
2005-04-25 |
2010-10-05 |
Amgen Fremont Inc. |
Antibodies to myostatin
|
AU2006238930B2
(en)
|
2005-04-26 |
2010-12-23 |
Pfizer Inc. |
P-cadherin antibodies
|
JO3058B1
(en)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
Anti-IL-6 Antibodies,Compositions,Methods and uses
|
WO2006121852A2
(en)
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
RU2007145509A
(en)
*
|
2005-05-09 |
2009-06-20 |
Гликарт Биотехнологи Аг (Ch) |
ANTIGEN BINDING MOLECULES HAVING MODIFIED FC SITES AND VARIABLE BINDING WITH FC RECEPTORS
|
AR053272A1
(en)
|
2005-05-11 |
2007-04-25 |
Hoffmann La Roche |
DETERMINATION OF RESPONSIVES TO CHEMOTHERAPY
|
EP2295066B1
(en)
|
2005-05-25 |
2016-04-27 |
CureDM Group Holdings, LLC |
Peptides, derivatives and analogs thereof, and methods of using same
|
GB0510790D0
(en)
|
2005-05-26 |
2005-06-29 |
Syngenta Crop Protection Ag |
Anti-CD16 binding molecules
|
AU2006261920A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Llc |
Antibody formulations having optimized aggregation and fragmentation profiles
|
WO2007005955A2
(en)
|
2005-06-30 |
2007-01-11 |
Centocor, Inc. |
Anti-il-23 antibodies, compositions, methods and uses
|
PT1904104E
(en)
|
2005-07-08 |
2013-11-21 |
Biogen Idec Inc |
Sp35 antibodies and uses thereof
|
US20070190047A1
(en)
*
|
2005-07-29 |
2007-08-16 |
Amgen, Inc. |
Formulations that inhibit protein aggregation
|
AU2006279945B2
(en)
|
2005-08-10 |
2012-04-12 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant FC regions and methods of using same
|
BRPI0615026A8
(en)
|
2005-08-19 |
2018-03-06 |
Abbott Lab |
double variable domain immunoglobulin and its uses
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
EP2500358A3
(en)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US7612181B2
(en)
*
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CA2620195A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
PT2447283E
(en)
|
2005-09-07 |
2015-10-08 |
Pfizer |
Human monoclonal antibodies to activin receptor-like kinase-1 (alk-1)
|
EP1928905B1
(en)
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
TW200730825A
(en)
|
2005-10-21 |
2007-08-16 |
Genenews Inc |
Method and apparatus for correlating levels of biomarker products with disease
|
KR20150055628A
(en)
|
2005-11-04 |
2015-05-21 |
제넨테크, 인크. |
Use of complement pathway inhibitors to treat ocular diseases
|
KR20080080109A
(en)
|
2005-11-04 |
2008-09-02 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
EA014900B1
(en)
|
2005-11-07 |
2011-02-28 |
Зе Скрипс Ресеч Инститьют |
Compositions and methods for controlling tissue factor signaling specificity
|
ES2340205T3
(en)
|
2005-11-12 |
2010-05-31 |
Eli Lilly And Company |
ANTI-EGFR ANTIBODIES.
|
PT2289909E
(en)
|
2005-11-30 |
2015-02-10 |
Abbvie Inc |
Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
|
KR20140087058A
(en)
|
2005-11-30 |
2014-07-08 |
애브비 인코포레이티드 |
Monoclonal antibodies against amyloid beta protein and uses thereof
|
US9387242B2
(en)
|
2005-12-02 |
2016-07-12 |
Icahn School Of Medicine At Mount Sinai |
Chimeric viruses presenting non-native surface proteins and uses thereof
|
EP1965827B1
(en)
|
2005-12-02 |
2015-02-25 |
Biogen Idec MA Inc. |
Treatment of conditions involving demyelination
|
CA2630157C
(en)
|
2005-12-07 |
2018-01-09 |
Medarex, Inc. |
Ctla-4 antibody dosage escalation regimens
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
AR056857A1
(en)
*
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
|
NL2000439C2
(en)
|
2006-01-20 |
2009-03-16 |
Quark Biotech |
Therapeutic applications of inhibitors of RTP801.
|
WO2007089601A2
(en)
|
2006-01-27 |
2007-08-09 |
Biogen Idec Ma Inc. |
Nogo receptor antagonists
|
BRPI0713426A2
(en)
|
2006-06-14 |
2012-10-09 |
Macrogenics Inc |
methods of treating, slowing the progression, or ameliorating one or more symptoms of a disorder, and preventing or delaying the onset of a disorder
|
EP2029173B1
(en)
|
2006-06-26 |
2016-07-20 |
MacroGenics, Inc. |
Fc riib-specific antibodies and methods of use thereof
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
AU2007274738B2
(en)
|
2006-07-18 |
2013-11-28 |
Sanofi-Aventis |
Antagonist antibody against EphA2 for the treatment of cancer
|
PL2511301T3
(en)
|
2006-08-04 |
2018-05-30 |
Medimmune Limited |
Human antibodies to erbb 2
|
CA2661782C
(en)
|
2006-08-28 |
2019-04-16 |
La Jolla Institute For Allergy And Immunology |
Antagonistic human light-specific human monoclonal antibodies
|
UA115964C2
(en)
|
2006-09-08 |
2018-01-25 |
Еббві Айрленд Анлімітед Компані |
INTERLAYKIN-13-Binding Protein
|
US20100008910A1
(en)
|
2006-09-12 |
2010-01-14 |
John Chant |
Methods and compositions for the diagnosis and treatment of cancer
|
MX2009003635A
(en)
*
|
2006-10-06 |
2009-04-22 |
Amgen Inc |
Stable formulations.
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
EP2407548A1
(en)
|
2006-10-16 |
2012-01-18 |
MedImmune, LLC |
Molecules with reduced half-lives, compositions and uses thereof
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
AU2007309616B2
(en)
*
|
2006-10-20 |
2011-10-06 |
Amgen Inc. |
Stable polypeptide formulations
|
WO2008064306A2
(en)
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
FR2909092B1
(en)
*
|
2006-11-24 |
2012-10-19 |
Pf Medicament |
NEW ANTI-PROLIFERATION ANTIBODIES
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2687232A1
(en)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Methods of treating systemic lupus erythematosus
|
JP5386364B2
(en)
|
2006-12-18 |
2014-01-15 |
ジェネンテック, インコーポレイテッド |
Anti-Notch3 antagonist antibodies and their use in the prevention and treatment of Notch3-related diseases
|
WO2008079976A2
(en)
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Dimeric high affinity egfr constructs and uses thereof
|
WO2008079982A2
(en)
*
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Liposome composition for targeting egfr receptor
|
WO2008079973A2
(en)
*
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Egfr binding peptides and uses thereof
|
EP2094303A1
(en)
*
|
2006-12-22 |
2009-09-02 |
Novelix Therapeutics Gmbh |
Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof
|
PT2099826E
(en)
|
2007-01-05 |
2014-01-09 |
Univ Zuerich |
Anti-beta-amyloid antibody and uses thereof
|
LT2740744T
(en)
|
2007-01-09 |
2018-05-10 |
Biogen Ma Inc. |
Sp35 antibodies and uses thereof
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
AU2008205512B2
(en)
|
2007-01-16 |
2014-06-12 |
Abbvie Inc. |
Methods for treating psoriasis
|
WO2008091701A2
(en)
|
2007-01-25 |
2008-07-31 |
Dana-Farber Cancer Institute |
Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
|
KR20080074683A
(en)
*
|
2007-02-09 |
2008-08-13 |
삼성전자주식회사 |
Method and apparatus for digital rights management
|
WO2008101184A2
(en)
|
2007-02-16 |
2008-08-21 |
The Board Of Trustees Of Southern Illinois University |
Arl-1 specific antibodies
|
US8685666B2
(en)
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
MX338151B
(en)
|
2007-03-01 |
2016-04-05 |
Symphogen As |
Recombinant anti-epidermal growth factor receptor antibody compositions.
|
WO2008109440A2
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
RS56422B1
(en)
|
2007-03-13 |
2018-01-31 |
Amgen Inc |
K-ras mutations and anti-egfr antibody therapy
|
PT2412828E
(en)
|
2007-03-13 |
2013-08-02 |
Amgen Inc |
K-ras and b-raf mutations and anti-egfr antibody therapy
|
JP5618549B2
(en)
|
2007-03-15 |
2014-11-05 |
ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド |
Method of treatment using EGFR antibody and SRC inhibitor and related preparation
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
US20110130544A1
(en)
|
2007-03-30 |
2011-06-02 |
Medimmune, Llc |
Antibodies with decreased deamidation profiles
|
UY30994A1
(en)
|
2007-04-02 |
2008-11-28 |
Amgen Fremont Inc |
ANTI-IGE ANTIBODIES
|
SG10201503254TA
(en)
|
2007-05-14 |
2015-06-29 |
Medimmune Llc |
Methods of reducing eosinophil levels
|
CA3006428A1
(en)
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
MX2009013816A
(en)
|
2007-06-21 |
2010-02-24 |
Macrogenics Inc |
Covalent diabodies and uses thereof.
|
US20100322939A1
(en)
*
|
2007-06-21 |
2010-12-23 |
Genmab A/S |
Novel methods for treating egfr-associated tumors
|
JP5532486B2
(en)
|
2007-08-14 |
2014-06-25 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
Monoclonal antibody 175 targeting EGF receptor and derivatives and uses thereof
|
CA2697032C
(en)
|
2007-08-22 |
2021-09-14 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
UA117446C2
(en)
|
2007-08-29 |
2018-08-10 |
Санофі-Авентіс |
HUMANIZED ANTIBODY TO CXCR5
|
CN101896499B
(en)
|
2007-08-30 |
2014-02-12 |
库尔Dm股份有限公司 |
Compositions and methods of using proislet peptides and analogs thereof
|
CA2698809C
(en)
*
|
2007-09-14 |
2023-10-17 |
Amgen Inc. |
Homogeneous antibody populations
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
US7985559B2
(en)
|
2007-10-19 |
2011-07-26 |
Amgen Inc. |
Methods of selecting epidermal growth factor receptor (EGFR) binding agents
|
US8663980B2
(en)
|
2007-10-26 |
2014-03-04 |
Janssen Biotech, Inc. |
Vectors, host cells, and methods of production and uses
|
SI2219452T1
(en)
|
2007-11-05 |
2016-03-31 |
Medimmune, Llc |
Methods of treating scleroderma
|
EP2225275A4
(en)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
Protein formulation
|
JP2011507933A
(en)
|
2007-12-26 |
2011-03-10 |
バイオテスト・アクチエンゲゼルシヤフト |
Methods for reducing cytotoxic side effects and improving efficacy of immune complexes
|
AR069978A1
(en)
|
2007-12-26 |
2010-03-03 |
Dana Farber Cancer Inst Inc |
METHODS AND AGENTS TO IMPROVE THE RECOGNITION OF TUMOR CELLS THAT EXPRESS CD 138
|
US8637026B2
(en)
|
2007-12-26 |
2014-01-28 |
Vaccinex, Inc. |
Anti-C35 antibody combination therapies and methods
|
JP5817034B2
(en)
|
2007-12-26 |
2015-11-18 |
バイオテスト・アクチエンゲゼルシヤフト |
Immune complex targeting CD138 and use thereof
|
EP3825329A1
(en)
|
2007-12-26 |
2021-05-26 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
EP2238168B8
(en)
|
2007-12-26 |
2014-07-23 |
Biotest AG |
Agents targeting cd138 and uses thereof
|
US8557243B2
(en)
*
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
US8454960B2
(en)
*
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
US8557242B2
(en)
*
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US20110033378A1
(en)
|
2008-01-18 |
2011-02-10 |
Medlmmune, Llc. |
Cysteine Engineered Antibodies For Site-Specific Conjugation
|
TWI472339B
(en)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
|
WO2009095480A1
(en)
*
|
2008-01-30 |
2009-08-06 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
PT2250279E
(en)
|
2008-02-08 |
2016-06-03 |
Medimmune Llc |
Anti-ifnar1 antibodies with reduced fc ligand affinity
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
EP2262522A1
(en)
*
|
2008-03-07 |
2010-12-22 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
AU2009225797A1
(en)
|
2008-03-18 |
2009-09-24 |
Abbvie Inc. |
Methods for treating psoriasis
|
US20110020368A1
(en)
|
2008-03-25 |
2011-01-27 |
Nancy Hynes |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
EP2604280A3
(en)
*
|
2008-03-27 |
2013-10-16 |
ZymoGenetics, Inc. |
Compositions and methods for inhibiting PDGFRBETA and VEGF-A
|
PE20091827A1
(en)
*
|
2008-04-11 |
2009-11-20 |
Galaxy Biotech Llc |
COMBINATION OF INHIBITOR HGF AND INHIBITOR EGF FOR THE TREATMENT OF CANCER
|
EP2281882A4
(en)
|
2008-04-25 |
2012-03-21 |
Toray Industries |
Nucleic acid containing chimeric gene derived from hepatitis type-c virus
|
CA2722466A1
(en)
|
2008-04-29 |
2009-11-05 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
CA2975228C
(en)
|
2008-05-02 |
2020-07-21 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
ES2579554T3
(en)
|
2008-05-09 |
2016-08-12 |
Abbvie Deutschland Gmbh & Co Kg |
Antibodies for the recipient of advanced glycation terminal products (RAGE) and uses thereof
|
EP2304439A4
(en)
|
2008-05-29 |
2012-07-04 |
Nuclea Biotechnologies Llc |
Anti-phospho-akt antibodies
|
WO2009149189A2
(en)
*
|
2008-06-03 |
2009-12-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
TW201006485A
(en)
|
2008-06-03 |
2010-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
TW201014602A
(en)
|
2008-07-08 |
2010-04-16 |
Abbott Lab |
Prostaglandin E2 binding proteins and uses thereof
|
JP5674654B2
(en)
|
2008-07-08 |
2015-02-25 |
アッヴィ・インコーポレイテッド |
Prostaglandin E2 double variable domain immunoglobulin and use thereof
|
CA2729961C
(en)
|
2008-07-09 |
2018-05-01 |
Biogen Idec Ma Inc. |
Li113, li62 variant co2, anti-lingo antibodies
|
DK2315747T3
(en)
|
2008-07-21 |
2018-02-26 |
Brigham & Womens Hospital Inc |
Methods and Compositions of Synthetic Beta-1.6 Glucosamine Oligosaccharides
|
CA2733642A1
(en)
|
2008-08-14 |
2010-02-18 |
Cephalon Australia Pty Ltd |
Anti-il-12/il-23 antibodies
|
EP2321351B1
(en)
|
2008-08-18 |
2017-11-01 |
Pfizer Inc. |
Antibodies to ccr2
|
CN102137874B
(en)
*
|
2008-08-29 |
2015-02-18 |
西福根有限公司 |
Recombinant anti-epidermal growth factor receptor antibody compositions
|
US8163497B2
(en)
|
2008-09-07 |
2012-04-24 |
Glyconex Inc. |
Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
|
EP3524620A1
(en)
|
2008-10-14 |
2019-08-14 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
CA2741523C
(en)
|
2008-10-24 |
2022-06-21 |
Jonathan S. Towner |
Human ebola virus species and compositions and methods thereof
|
WO2010052288A1
(en)
|
2008-11-07 |
2010-05-14 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
EP2191842A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
EP2191841A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
EP2191843A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
SG171812A1
(en)
*
|
2008-12-04 |
2011-07-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
SI2786762T1
(en)
|
2008-12-19 |
2019-07-31 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
CA2748757A1
(en)
|
2008-12-31 |
2010-07-08 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
EP2385955B1
(en)
|
2009-01-12 |
2020-08-12 |
CytomX Therapeutics, Inc. |
Modified antibody compositions, methods of making and using thereof
|
KR101245929B1
(en)
|
2009-01-20 |
2013-03-22 |
호메이욘 에이치. 자데흐 |
Antibody mediated osseous regeneration
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
WO2010096838A2
(en)
*
|
2009-02-23 |
2010-08-26 |
Cytomx Therapeutics, Llc |
Proproteins and methods of use thereof
|
AR075798A1
(en)
|
2009-03-05 |
2011-04-27 |
Abbott Lab |
PROTEINS OF UNION TO IL-17 (INTERLEUQUINA 17)
|
WO2010100247A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Novel therapy for anxiety
|
KR20130080871A
(en)
|
2009-03-20 |
2013-07-15 |
제넨테크, 인크. |
Bispecific anti-her antibodies
|
AU2010228990A1
(en)
|
2009-03-24 |
2011-10-27 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against LIGHT and uses thereof
|
WO2010117786A1
(en)
|
2009-03-30 |
2010-10-14 |
Mount Sinai School Of Medicine Of New York University |
Influenza virus vaccines and uses thereof
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
KR20110138412A
(en)
|
2009-04-16 |
2011-12-27 |
애보트 바이오테라퓨틱스 코포레이션 |
ANTI-TNF-α ANTIBODIES AND THEIR USES
|
SG177265A1
(en)
|
2009-06-17 |
2012-02-28 |
Abbott Biotherapeutics Corp |
Anti-vegf antibodies and their uses
|
EP2445520A4
(en)
|
2009-06-22 |
2013-03-06 |
Medimmune Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
EP2461870B1
(en)
|
2009-07-22 |
2017-09-06 |
Biothera, Inc. |
Composition comprising beta-glucan and an egf-r antibody or an egf-r antagonist for use in the treatment of kras-mutated tumors
|
US9217157B2
(en)
|
2009-07-27 |
2015-12-22 |
Icahn School Of Medicine At Mount Sinai |
Recombinant influenza viruses and uses thereof
|
UY32808A
(en)
*
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
IMMUNOGLOBULINS AS A DUAL VARIABLE DOMAIN AND USES OF THE SAME
|
JP5845180B2
(en)
|
2009-07-30 |
2016-01-20 |
モウント シナイ スクール オフ メディシネ |
Influenza viruses and their use
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
EA023179B1
(en)
|
2009-08-13 |
2016-05-31 |
Круселл Холланд Б.В. |
Antibodies against human respiratory syncytial virus (rsv) and methods of use
|
CN105131112A
(en)
|
2009-08-29 |
2015-12-09 |
Abbvie公司 |
Therapeutic dll4 binding proteins
|
AU2010289527C1
(en)
|
2009-09-01 |
2014-10-30 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
ES2354922B1
(en)
|
2009-09-02 |
2012-02-07 |
Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron |
MARKERS FOR THE SELECTION OF PERSONALIZED THERAPIES FOR THE TREATMENT OF THE C�? NCER.
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
AR078161A1
(en)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
|
EP2480573A1
(en)
|
2009-09-22 |
2012-08-01 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
UY32914A
(en)
|
2009-10-02 |
2011-04-29 |
Sanofi Aventis |
ANTIBODIES SPECIFICALLY USED TO THE EPHA2 RECEIVER
|
WO2011044368A1
(en)
|
2009-10-07 |
2011-04-14 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
EP2488658A4
(en)
|
2009-10-15 |
2013-06-19 |
Abbvie Inc |
Dual variable domain immunoglobulins and uses thereof
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
CA2777825A1
(en)
|
2009-10-28 |
2011-05-19 |
Abbott Biotherapeutics Corp. |
Anti-egfr antibodies and their uses
|
UY32979A
(en)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
|
EP2494070A2
(en)
|
2009-10-30 |
2012-09-05 |
Bristol-Myers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
JP2013509874A
(en)
|
2009-11-04 |
2013-03-21 |
エラスムス ユニバーシティ メディカル センター ロッテルダム |
Novel compounds for modulating angiogenesis and methods of treatment using these compounds
|
KR20120103587A
(en)
|
2009-11-12 |
2012-09-19 |
제넨테크, 인크. |
A method of promoting dendritic spine density
|
NO2719708T3
(en)
|
2009-11-13 |
2018-03-24 |
|
|
CA2781682A1
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
JP5951498B2
(en)
|
2009-12-08 |
2016-07-13 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
Monoclonal antibody against RGMA protein for use in the treatment of retinal nerve fiber layer degeneration
|
WO2011084496A1
(en)
|
2009-12-16 |
2011-07-14 |
Abbott Biotherapeutics Corp. |
Anti-her2 antibodies and their uses
|
TW201129565A
(en)
|
2010-01-12 |
2011-09-01 |
Hoffmann La Roche |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
US20110189178A1
(en)
*
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
MX341687B
(en)
|
2010-02-10 |
2016-08-30 |
Immunogen Inc |
Cd20 antibodies and uses thereof.
|
SI2536748T1
(en)
|
2010-02-18 |
2014-12-31 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
RU2016146198A
(en)
|
2010-03-02 |
2018-12-19 |
Эббви Инк. |
THERAPEUTIC DLL4-BINDING PROTEINS
|
WO2011107664A1
(en)
|
2010-03-04 |
2011-09-09 |
Hospital District Of Southwest Finland |
Method for selecting patients for treatment with an egfr inhibitor
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
CA2793024A1
(en)
|
2010-03-17 |
2011-09-22 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
MX341925B
(en)
|
2010-03-29 |
2016-09-07 |
Zymeworks Inc |
Antibodies with enhanced or suppressed effector function.
|
JP2013526849A
(en)
|
2010-03-30 |
2013-06-27 |
モウント シナイ スクール オフ メディシネ |
Influenza virus vaccine and use thereof
|
EP2371369A1
(en)
|
2010-04-01 |
2011-10-05 |
Institut Gustave Roussy (IGR) |
EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
|
ES2684475T3
(en)
|
2010-04-15 |
2018-10-03 |
Abbvie Inc. |
Proteins that bind to beta amyloid
|
CA2796055A1
(en)
*
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
Human fgf receptor and .beta.-klotho binding proteins
|
CA2793892A1
(en)
|
2010-04-16 |
2011-10-20 |
Elizabeth Punnoose |
Foxo3a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
|
US20130034543A1
(en)
|
2010-04-19 |
2013-02-07 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Modulating xrn1
|
TWI522365B
(en)
|
2010-05-14 |
2016-02-21 |
艾伯維有限公司 |
Il-1 binding proteins
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011156617A2
(en)
|
2010-06-09 |
2011-12-15 |
Aveo Pharmaceuticals, Inc. |
Anti-egfr antibodies
|
WO2011154485A1
(en)
|
2010-06-10 |
2011-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
JP2013530981A
(en)
|
2010-06-25 |
2013-08-01 |
アストン ユニバーシティ |
Glycoproteins with lipid mobilization properties and therapeutic uses thereof
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(en)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
|
KR101896124B1
(en)
|
2010-07-09 |
2018-09-07 |
얀센 백신스 앤드 프리벤션 비.브이. |
Anti-human respiratory syncytial virus(rsv) antibodies and methods of use
|
WO2012016227A2
(en)
|
2010-07-29 |
2012-02-02 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
AU2011286024B2
(en)
|
2010-08-02 |
2014-08-07 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
BR112013002578A2
(en)
|
2010-08-03 |
2019-05-14 |
Abbvie Inc. |
double variable domain immunoglobins and their uses
|
SG187198A1
(en)
|
2010-08-05 |
2013-03-28 |
Amgen Inc |
Dipeptides to enhance yield and viability from cell cultures
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
MX358739B
(en)
|
2010-08-14 |
2018-09-03 |
Abbvie Inc Star |
Amyloid-beta binding proteins.
|
AU2011291462A1
(en)
|
2010-08-19 |
2013-03-14 |
Zoetis Belgium S.A. |
Anti-NGF antibodies and their use
|
WO2012024659A2
(en)
|
2010-08-20 |
2012-02-23 |
Massachusetts Institute Of Technology |
Antibody-based constructs directed against tyrosine kinase receptors
|
TW201211252A
(en)
|
2010-08-26 |
2012-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US20120089541A1
(en)
|
2010-08-31 |
2012-04-12 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
EP2614080A1
(en)
|
2010-09-10 |
2013-07-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
AR082974A1
(en)
|
2010-09-15 |
2013-01-23 |
Hoffmann La Roche |
DERIVATIVES OF AZABENZOTIAZOL, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, METHOD TO PREPARE THEM AND USE OF THEM TO TREAT INFLAMMATORY DISEASES
|
HUE058896T2
(en)
|
2010-10-01 |
2022-09-28 |
Modernatx Inc |
Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
|
EP3581206A1
(en)
|
2010-10-22 |
2019-12-18 |
Seattle Genetics, Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the p13k-akt mtor pathway
|
EA201390472A1
(en)
|
2010-10-29 |
2014-02-28 |
Иммьюноджен, Инк. |
NEW MOLECULES CONNECTING WITH EGFR AND THEIR IMMUNOCONJUGATES
|
BR112013010569A2
(en)
|
2010-10-29 |
2017-07-04 |
Immunogen Inc |
non-antagonistic and immunoconjugated egfr binding molecules thereof
|
US9309322B2
(en)
|
2010-11-12 |
2016-04-12 |
Scott & White Healthcare (Swh) |
Antibodies to tumor endothelial marker 8
|
WO2012065937A1
(en)
|
2010-11-15 |
2012-05-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Anti-fungal agents
|
EP2640384A1
(en)
|
2010-11-18 |
2013-09-25 |
Synta Pharmaceuticals Corp. |
Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
|
BR112013011520A2
(en)
|
2010-11-19 |
2019-09-24 |
Hoffmann La Roche |
pyrazolo pyridines and pyrazolo pyridines and their use as tyk2 inhibitors
|
UA112170C2
(en)
|
2010-12-10 |
2016-08-10 |
Санофі |
ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB
|
MY163368A
(en)
|
2010-12-21 |
2017-09-15 |
Abbvie Inc |
Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
EP2668209B8
(en)
|
2011-01-24 |
2021-08-11 |
Gilead Sciences, Inc. |
Antibodies selective for cells presenting egfr at high density
|
EP3763740A1
(en)
|
2011-01-26 |
2021-01-13 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
EP3235508B1
(en)
|
2011-03-16 |
2020-12-30 |
Sanofi |
Compositions comprising a dual v region antibody-like protein
|
JP2014511687A
(en)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
Engineered nucleic acid delivery and formulation
|
US8628773B2
(en)
|
2011-04-07 |
2014-01-14 |
Amgen Inc. |
Antigen binding proteins
|
LT2699293T
(en)
|
2011-04-20 |
2019-04-25 |
Amgen Inc. |
Autoinjector apparatus
|
MX338353B
(en)
|
2011-04-20 |
2016-04-13 |
Medimmune Llc |
Antibodies and other molecules that bind b7-h1 and pd-1.
|
WO2012145682A1
(en)
|
2011-04-21 |
2012-10-26 |
Amgen Inc. |
A method for culturing mammalian cells to improve recombinant protein production
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
AU2012259162C1
(en)
|
2011-05-21 |
2020-05-21 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
US9181553B2
(en)
|
2011-06-06 |
2015-11-10 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Method of treatment of breast cancers over-expressing the SHP2 signature genes
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
PL2718320T3
(en)
|
2011-06-10 |
2018-06-29 |
Medimmune Limited |
Anti-pseudomonas psl binding molecules and uses thereof
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
CN103687964A
(en)
|
2011-06-20 |
2014-03-26 |
特拉斯雷神诺癌症医药有限公司 |
Method for predicting the clinical response to chemotherapy in a subject with cancer
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
WO2013006479A2
(en)
|
2011-07-01 |
2013-01-10 |
Amgen Inc. |
Mammalian cell culture
|
WO2013009868A1
(en)
|
2011-07-11 |
2013-01-17 |
Yale University |
Compositions and methods for making selenocysteine containing polypeptides
|
WO2019071023A1
(en)
|
2017-10-04 |
2019-04-11 |
Yale University |
Compositions and methods for making selenocysteine containing polypeptides
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
EP2734236A4
(en)
|
2011-07-13 |
2015-04-15 |
Abbvie Inc |
Methods and compositions for treating asthma using anti-il-13 antibodies
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
BR112014003237A2
(en)
|
2011-08-12 |
2017-04-25 |
Hoffmann La Roche |
indazole compounds, compositions and methods of use
|
JP6120848B2
(en)
|
2011-08-15 |
2017-04-26 |
メディミューン,エルエルシー |
Anti-B7-H4 antibody and use thereof
|
BR112014003431A2
(en)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
antibody, nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, pharmaceutical agent, use of the antibody, method of treating an individual who has cancer, and time-lapse method for tumor recurrence
|
CN103857700A
(en)
|
2011-08-26 |
2014-06-11 |
梅里麦克制药股份有限公司 |
Tandem FC bispecific antibodies
|
AU2012301656A1
(en)
|
2011-09-02 |
2014-01-16 |
Amgen Inc. |
Pharmaceutical product and method of analysing light exposure of a pharmaceutical product
|
WO2013066491A1
(en)
|
2011-09-09 |
2013-05-10 |
Amgen Inc. |
Use of human papillomavirus status in establishing use of an agent that binds egfr in the treatment of cancer
|
JP6216317B2
(en)
|
2011-09-09 |
2017-10-18 |
メディミューン リミテッド |
Anti-Siglec-15 antibody and use thereof
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
WO2013041539A1
(en)
|
2011-09-20 |
2013-03-28 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
SG11201400743VA
(en)
|
2011-09-20 |
2014-04-28 |
Sinai School Medicine |
Influenza virus vaccines and uses thereof
|
RU2648950C2
(en)
|
2011-10-03 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Modified nucleosides, nucleotides and nucleic acids and their application
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
EP2766392B1
(en)
|
2011-10-10 |
2019-07-17 |
Xencor, Inc. |
A method for purifying antibodies
|
US20140309229A1
(en)
|
2011-10-13 |
2014-10-16 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
BR112014009799A2
(en)
|
2011-10-24 |
2017-06-13 |
Abbvie Inc |
tnf directed immunoligants
|
TW201323440A
(en)
|
2011-10-24 |
2013-06-16 |
Abbvie Inc |
Immunobinders directed against sclerostin
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
CN104053671A
(en)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
Antibodies and methods of treating cancer
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
AU2012332588B2
(en)
|
2011-11-01 |
2017-09-07 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
EP2773651B1
(en)
|
2011-11-03 |
2020-12-23 |
The Trustees of the University of Pennsylvania |
Isolated b7-h4 specific compositions and methods of use thereof
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
KR20140076602A
(en)
|
2011-11-08 |
2014-06-20 |
화이자 인코포레이티드 |
Methods of treating inflammatory disorders using anti-m-csf antibodies
|
EP2776838A1
(en)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Early diagnostic of neurodegenerative diseases
|
WO2013070821A1
(en)
|
2011-11-08 |
2013-05-16 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
AU2012340174A1
(en)
|
2011-11-16 |
2014-05-29 |
Amgen Inc. |
Methods of treating epidermal growth factor deletion mutant VIII related disorders
|
AU2012340686A1
(en)
|
2011-11-21 |
2014-06-19 |
Immunogen, Inc. |
Method of treatment of tumors that are resistant to EGFR therapies by EGFR antibody cytotoxic agent conjugate
|
AU2012346540C1
(en)
|
2011-11-30 |
2019-07-04 |
Genentech, Inc. |
ErbB3 mutations in cancer
|
KR20140100571A
(en)
|
2011-12-08 |
2014-08-14 |
바이오테스트 아게 |
Uses of immunoconjugates targeting cd138
|
EP2791175A2
(en)
|
2011-12-14 |
2014-10-22 |
Abbvie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
EP3800200A1
(en)
|
2011-12-14 |
2021-04-07 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
AR089231A1
(en)
|
2011-12-15 |
2014-08-06 |
Amgen Inc |
FLOCULATION METHOD
|
EP2791160B1
(en)
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Modified mrna compositions
|
CN103172741B
(en)
*
|
2011-12-20 |
2018-04-27 |
智翔(上海)医药科技有限公司 |
Full people source anti-egfr antibodies
|
WO2013093809A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
WO2013102042A2
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual specific binding proteins directed against il-13 and/or il-17
|
WO2013102825A1
(en)
|
2012-01-02 |
2013-07-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
EP2804948B1
(en)
|
2012-01-20 |
2020-04-15 |
The Government of The Hong Kong Special Administrative Region of The People's Republic of China |
A novel paramyxovirus and uses thereof
|
PE20142168A1
(en)
|
2012-01-27 |
2015-01-17 |
AbbVie Deutschland GmbH and Co KG |
COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH THE DEGENERATION OF NEURITES
|
IN2014MN01781A
(en)
*
|
2012-02-08 |
2015-07-03 |
Igm Biosciences Inc |
|
CA2864092C
(en)
|
2012-02-10 |
2021-06-29 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
WO2013120554A1
(en)
|
2012-02-15 |
2013-08-22 |
Novo Nordisk A/S |
Antibodies that bind peptidoglycan recognition protein 1
|
LT2814844T
(en)
|
2012-02-15 |
2017-10-25 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
BR112014024017A8
(en)
|
2012-03-27 |
2017-07-25 |
Genentech Inc |
METHODS FOR TREATMENT OF A TYPE OF CANCER, FOR TREATMENT OF CARCINOMA, FOR SELECTING A THERAPY AND FOR QUANTIFICATION AND HER3 INHIBITORS
|
EP2831112A1
(en)
|
2012-03-29 |
2015-02-04 |
Friedrich Miescher Institute for Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
AU2013243951A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of secreted proteins
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
EP2836514A4
(en)
|
2012-04-13 |
2015-12-30 |
Childrens Medical Center |
Tiki inhibitors
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
US9505833B2
(en)
|
2012-04-20 |
2016-11-29 |
Abbvie Inc. |
Human antibodies that bind human TNF-alpha and methods of preparing the same
|
WO2013166043A1
(en)
|
2012-05-02 |
2013-11-07 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
NZ702178A
(en)
|
2012-05-14 |
2017-01-27 |
Biogen Ma Inc |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
JP6122948B2
(en)
|
2012-05-15 |
2017-04-26 |
モルフォテック, インコーポレイテッド |
Methods for the treatment of gastric cancer
|
JP6441792B2
(en)
*
|
2012-05-17 |
2018-12-19 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Antigen binding protein that binds to EGFR
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
AU2012380717B2
(en)
|
2012-05-24 |
2018-08-16 |
Fundacio Institucio Catalana De Recerca I Estudis Avancats |
Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
US9617334B2
(en)
|
2012-06-06 |
2017-04-11 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
SG11201408161RA
(en)
|
2012-06-08 |
2015-01-29 |
Sutro Biopharma Inc |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
EP2866831A1
(en)
|
2012-06-29 |
2015-05-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
EP2870242A1
(en)
|
2012-07-05 |
2015-05-13 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
US20150224190A1
(en)
|
2012-07-06 |
2015-08-13 |
Mohamed Bentires-Alj |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
EA201590208A1
(en)
|
2012-07-13 |
2015-11-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
CAR ACTIVITY STRENGTHENING BY CAR BY JOINT INTRODUCTION OF BISPECIFIC ANTIBODIES
|
CN104519887B
(en)
|
2012-08-07 |
2017-06-27 |
诺华股份有限公司 |
Drug regimen comprising B Raf inhibitor, EGFR inhibitor and optional PI3K alpha inhibitors
|
SI3584255T1
(en)
|
2012-08-31 |
2022-05-31 |
Sutro Biopharma, Inc |
Modified amino acids comprising an azido group
|
US9206390B2
(en)
|
2012-09-02 |
2015-12-08 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
NO2760138T3
(en)
|
2012-10-01 |
2018-08-04 |
|
|
AR092745A1
(en)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
COMPOSITIONS THAT INCLUDE AN ANTI-FAP UNION DOMAIN AND METHODS TO MAKE WHITE IN STROMAL CELLS FOR THE TREATMENT OF CANCER
|
WO2014055771A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
EP2839860B1
(en)
|
2012-10-12 |
2019-05-01 |
MedImmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
AU2013334493B2
(en)
|
2012-10-26 |
2018-11-29 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
TW201422236A
(en)
|
2012-11-01 |
2014-06-16 |
Abbvie Inc |
Stable dual variable domain immunoglobulin protein formulations
|
RU2017137740A
(en)
|
2012-11-01 |
2019-02-11 |
Эббви Инк. |
ANTI-VEGF / DLL4-IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATIONS
|
UY35148A
(en)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
HETERODIMERIC IMMUNOGLOBULINS
|
EP2922554B1
(en)
|
2012-11-26 |
2022-02-23 |
ModernaTX, Inc. |
Terminally modified rna
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
UA118255C2
(en)
|
2012-12-07 |
2018-12-26 |
Санофі |
Compositions comprising anti-cd38 antibodies and lenalidomide
|
AU2013362935B2
(en)
|
2012-12-18 |
2018-10-04 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccines and uses thereof
|
CA2894879A1
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
MX2015008117A
(en)
|
2012-12-21 |
2016-03-31 |
Amplimmune Inc |
Anti-h7cr antibodies.
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US20140199728A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
EP2943511B1
(en)
|
2013-01-14 |
2019-08-07 |
Xencor, Inc. |
Novel heterodimeric proteins
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
EP2951199A4
(en)
|
2013-01-31 |
2016-07-20 |
Univ Jefferson |
Fusion proteins for modulating regulatory and effector t cells
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
CN104994879A
(en)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
Methods of treating cancer and preventing drug resistance
|
KR20150143458A
(en)
|
2013-03-06 |
2015-12-23 |
메리맥 파마슈티컬즈, 인크. |
ANTI-C-MET Tandem Fc Bispecific Antibodies
|
BR112015021423A2
(en)
|
2013-03-06 |
2017-07-18 |
Genentech Inc |
cancer treatment methods, egfr antagonist-resistant cancer cells, cancer cells, methods of increasing the sensitivity and effectiveness of cancer treatment, and methods of delaying, treating cancer patients and extending
|
RU2723937C2
(en)
|
2013-03-13 |
2020-06-18 |
Санофи |
Compositions comprising cd38 antibodies and carfilzomib
|
JP6444902B2
(en)
|
2013-03-13 |
2018-12-26 |
メドイミューン・リミテッドMedImmune Limited |
Pyrrolobenzodiazepine and its conjugates
|
BR112015022545A2
(en)
|
2013-03-13 |
2017-07-18 |
Constellation Pharmaceuticals Inc |
pyrazole compounds and the uses thereof
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
EP4026596A1
(en)
|
2013-03-14 |
2022-07-13 |
Amgen, Inc |
Removal of leaked affinity purification ligand
|
JP2016520527A
(en)
|
2013-03-14 |
2016-07-14 |
パーカシュ ギル, |
Treatment of cancer using antibodies that bind to cell surface GRP78
|
MX362075B
(en)
|
2013-03-14 |
2019-01-07 |
Abbott Lab |
Hcv antigen-antibody combination assay and methods and compositions for use therein.
|
RU2015139054A
(en)
|
2013-03-14 |
2017-04-19 |
Дженентек, Инк. |
METHODS FOR TREATING CANCER AND PREVENTION OF DRUG RESISTANCE OF CANCER
|
EP3399053A1
(en)
|
2013-03-14 |
2018-11-07 |
Abbott Molecular Inc. |
Cell preparations and cell supports and their use in theranosis
|
TWI771890B
(en)
|
2013-03-14 |
2022-07-21 |
美商安美基公司 |
Methods for increasing mannose content of recombinant proteins
|
CN105209616A
(en)
|
2013-03-14 |
2015-12-30 |
雅培制药有限公司 |
HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014159960A1
(en)
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Antibodies against influenza virus hemagglutinin and uses thereof
|
CA2906417C
(en)
|
2013-03-14 |
2022-06-21 |
Robert Ziemann |
Hcv core lipid binding domain monoclonal antibodies
|
EP2970459A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Dual specific binding proteins directed against il-1beta and il-17
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
BR112015023084A2
(en)
|
2013-03-15 |
2017-11-21 |
Abbvie Biotechnology Ltd |
monoclonal anti-cd25 antibody or anti-cd25 binding fragment of a monoclonal antibody, antibody-drug conjugate, pharmaceutical composition, nucleic acid, vector, prokaryotic and eukaryotic host cell, method for producing an anti-cd25 antibody or binding fragment anti-cd25, and use of a monoclonal anti-cd25 antibody from an antibody-drug conjugate or pharmaceutical composition
|
JP6482525B2
(en)
|
2013-03-15 |
2019-03-13 |
メモリアル スローン ケタリング キャンサー センター |
High affinity anti-GD2 antibody
|
CA2904725C
(en)
|
2013-03-15 |
2022-04-12 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
CA2907181C
(en)
|
2013-03-15 |
2023-10-17 |
Viktor Roschke |
Multivalent and monovalent multispecific complexes and their uses
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
TWI639449B
(en)
|
2013-03-15 |
2018-11-01 |
美商安美基公司 |
Cassette for an injector
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
WO2014145907A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Targeting t cells with heterodimeric proteins
|
US20140377253A1
(en)
|
2013-03-15 |
2014-12-25 |
Abbvie Biotherapeutics Inc. |
Fc variants
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
KR20150130451A
(en)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
Methods of treating cancer and preventing cancer drug resistance
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
RU2015144033A
(en)
|
2013-03-15 |
2017-04-26 |
Эббви Байотекнолоджи Лтд. |
ANTIBODIES AGAINST CD25 AND THEIR APPLICATION
|
RU2652880C2
(en)
*
|
2013-04-07 |
2018-05-03 |
Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. |
Epidermal growth factor receptor antibody
|
JP6433085B2
(en)
|
2013-04-09 |
2018-12-05 |
ボストン バイオメディカル, インコーポレイテッド |
2-acetylnaphtho [2,3-b] furan-4,9-dione for use in the treatment of cancer
|
ES2906615T3
(en)
|
2013-04-19 |
2022-04-19 |
Cytune Pharma |
Cytokine-derived therapy with reduced vascular leak syndrome
|
TWI679019B
(en)
|
2013-04-29 |
2019-12-11 |
法商賽諾菲公司 |
Anti-il-4/anti-il-13 bispecific antibody formulations
|
AU2014262843B2
(en)
|
2013-05-06 |
2017-06-22 |
Scholar Rock, Inc. |
Compositions and methods for growth factor modulation
|
CN103290018B
(en)
*
|
2013-05-07 |
2015-07-29 |
南方医科大学 |
A kind of nucleic acid aptamer of being combined with Human epidermal growth factor receptor type III mutant specific and application thereof
|
BR112015029395A2
(en)
|
2013-05-24 |
2017-09-19 |
Medimmune Llc |
ANTI-B7-H5 ANTIBODIES AND THEIR USES
|
US9481901B2
(en)
|
2013-05-30 |
2016-11-01 |
Amgen Inc. |
Methods for increasing mannose content of recombinant proteins
|
NZ714765A
(en)
|
2013-06-06 |
2021-12-24 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
EP3632467B1
(en)
|
2013-06-07 |
2023-09-27 |
Duke University |
Inhibitors of complement factor h
|
KR20160034893A
(en)
|
2013-06-13 |
2016-03-30 |
패스트 포워드 파머슈티컬스 비.브이. |
CD40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an TGR5-receptor agonist, an FXR agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis
|
US9499628B2
(en)
|
2013-06-14 |
2016-11-22 |
Children's Hospital Medical Center |
Method of boosting the immune response in neonates
|
EP3016980B1
(en)
|
2013-07-05 |
2020-05-06 |
Formation Biologics Inc. |
Egfr antibody conjugates
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
EP3030902B1
(en)
|
2013-08-07 |
2019-09-25 |
Friedrich Miescher Institute for Biomedical Research |
New screening method for the treatment friedreich's ataxia
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
AU2014318017B2
(en)
|
2013-09-05 |
2020-02-06 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
EP3041474B1
(en)
|
2013-09-05 |
2020-03-18 |
Genentech, Inc. |
Antiproliferative compounds
|
CN110559435B
(en)
|
2013-09-11 |
2023-10-20 |
伊戈尔生物药品股份有限公司 |
Liquid protein formulations comprising ionic liquids
|
SG11201601770YA
(en)
|
2013-09-12 |
2016-04-28 |
Halozyme Inc |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
TW201605857A
(en)
|
2013-10-03 |
2016-02-16 |
赫孚孟拉羅股份公司 |
Therapeutic inhibitors of CDK8 and uses thereof
|
EA201690675A1
(en)
|
2013-10-03 |
2016-08-31 |
Модерна Терапьютикс, Инк. |
POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US20150147333A1
(en)
|
2013-10-18 |
2015-05-28 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
WO2015066027A2
(en)
|
2013-10-28 |
2015-05-07 |
Dots Devices, Inc. |
Allergen detection
|
US11130980B2
(en)
|
2013-10-31 |
2021-09-28 |
Amgen Inc. |
Use of monensin to regulate glycosylation of recombinant proteins
|
KR20160077155A
(en)
|
2013-10-31 |
2016-07-01 |
사노피 |
Specific anti-cd38 antibodies for treating human cancers
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
KR20160088884A
(en)
|
2013-12-12 |
2016-07-26 |
노파르티스 아게 |
Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
|
WO2015088346A1
(en)
|
2013-12-13 |
2015-06-18 |
Rijksuniversiteit Groningen |
Antibodies against staphylococcus aureus and uses thereof.
|
KR20240017102A
(en)
|
2013-12-17 |
2024-02-06 |
제넨테크, 인크. |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
KR20160099092A
(en)
|
2013-12-17 |
2016-08-19 |
제넨테크, 인크. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
ES2920677T3
(en)
|
2013-12-24 |
2022-08-08 |
Janssen Pharmaceutica Nv |
Anti-VISTA Antibodies and Fragments
|
EP2893939A1
(en)
|
2014-01-10 |
2015-07-15 |
Netris Pharma |
Anti-netrin-1 antibody
|
SG11201605640UA
(en)
|
2014-01-13 |
2016-08-30 |
Amgen Inc |
Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
|
KR102410393B1
(en)
|
2014-01-29 |
2022-06-16 |
암젠 인크 |
Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
US10106829B2
(en)
|
2014-01-29 |
2018-10-23 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
EP2915569A1
(en)
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
JP2017516458A
(en)
|
2014-03-24 |
2017-06-22 |
ジェネンテック, インコーポレイテッド |
Cancer treatment with c-met antagonist and correlation with HGF expression of c-met antagonist
|
JP6775422B2
(en)
|
2014-03-28 |
2020-10-28 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Bispecific antibody that binds to CD38 and CD3
|
PT3126394T
(en)
|
2014-03-31 |
2019-12-19 |
Hoffmann La Roche |
Anti-ox40 antibodies and methods of use
|
MX2016012779A
(en)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists.
|
MX2016012873A
(en)
|
2014-04-04 |
2017-03-07 |
Bionomics Inc |
Humanized antibodies that bind lgr5.
|
CA2983794A1
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
MX2016014761A
(en)
|
2014-05-16 |
2017-05-25 |
Amgen Inc |
Assay for detecting th1 and th2 cell populations.
|
EP3888690A3
(en)
|
2014-05-16 |
2021-10-20 |
MedImmune, LLC |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
PT3148579T
(en)
|
2014-05-28 |
2021-03-11 |
Ludwig Inst For Cancer Res Ltd |
Anti-gitr antibodies and methods of use thereof
|
MX2016015944A
(en)
|
2014-06-04 |
2017-08-15 |
Amgen Inc |
Methods for harvesting mammalian cell cultures.
|
EP3154579A1
(en)
|
2014-06-13 |
2017-04-19 |
Friedrich Miescher Institute for Biomedical Research |
New treatment against influenza virus
|
CA2952026A1
(en)
|
2014-06-13 |
2015-12-17 |
Tenboron Oy |
Conjugates comprising an anti-egfr1 antibody
|
WO2015198202A1
(en)
|
2014-06-23 |
2015-12-30 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
EP3164129A1
(en)
|
2014-07-01 |
2017-05-10 |
Friedrich Miescher Institute for Biomedical Research |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
MY178347A
(en)
|
2014-07-17 |
2020-10-08 |
Novo Nordisk As |
Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
SG11201701328XA
(en)
|
2014-09-02 |
2017-03-30 |
Immunogen Inc |
Methods for formulating antibody drug conjugate compositions
|
CN107074823B
(en)
|
2014-09-05 |
2021-05-04 |
基因泰克公司 |
Therapeutic compounds and uses thereof
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2016044694A1
(en)
|
2014-09-19 |
2016-03-24 |
Genentech, Inc. |
Use of cbp/ep300 and bet inhibitors for treatment of cancer
|
WO2016046768A1
(en)
|
2014-09-24 |
2016-03-31 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
AU2015325055B2
(en)
|
2014-10-01 |
2021-02-25 |
Eagle Biologics, Inc. |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
EP3204379B1
(en)
|
2014-10-10 |
2019-03-06 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
ES2855075T3
(en)
|
2014-10-17 |
2021-09-23 |
Novartis Ag |
Combination of ceritinib with an EGFR inhibitor
|
EP3209687A1
(en)
|
2014-10-23 |
2017-08-30 |
Innate Pharma |
Treatment of cancers using anti-nkg2a agents
|
BR112017008945A2
(en)
|
2014-10-31 |
2018-01-16 |
Abbvie Biotherapeutics Inc |
ANTI-CS1 ANTIBODIES AND PHARMACEUTICAL-ANTIBODY CONJUGATES
|
JP6879910B2
(en)
|
2014-10-31 |
2021-06-02 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Modification of gene expression in CART cells and their use
|
JP6884697B2
(en)
|
2014-10-31 |
2021-06-09 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Compositions and Methods for Stimulating and Expanding T Cells
|
EP3215850B1
(en)
|
2014-11-03 |
2019-07-03 |
F. Hoffmann-La Roche AG |
Assays for detecting t cell immune subsets and methods of use thereof
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
MA40940A
(en)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
|
MA40943A
(en)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
|
CN107108613B
(en)
|
2014-11-10 |
2020-02-25 |
基因泰克公司 |
Bromodomain inhibitors and uses thereof
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
WO2016077526A1
(en)
|
2014-11-12 |
2016-05-19 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
AU2015350242A1
(en)
|
2014-11-17 |
2017-06-29 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
CA2968372A1
(en)
|
2014-11-19 |
2016-05-26 |
Amgen Inc. |
Quantitation of glycan moiety in recombinant glycoproteins
|
EP3223845B1
(en)
|
2014-11-26 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd20
|
MA41019A
(en)
|
2014-11-26 |
2021-05-05 |
Xencor Inc |
HETERODIMERIC ANTIBODIES BINDING TO CD3 AND CD38 ANTIGENS
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
JP6771464B2
(en)
|
2014-11-27 |
2020-10-21 |
ジェネンテック, インコーポレイテッド |
4,5,6,7-Tetrahydro-1H-pyrazolo [4,3-C] Pyridine-3-amine compound as CBP and / or EP300 inhibitor
|
EP3227454B1
(en)
|
2014-12-01 |
2020-01-29 |
Amgen Inc. |
Process for manipulating the level of glycan content of a glycoprotein
|
EP3229836B1
(en)
|
2014-12-09 |
2019-11-13 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Human monoclonal antibodies against axl
|
WO2016094509A1
(en)
|
2014-12-09 |
2016-06-16 |
Abbvie Inc. |
Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
|
CN113209306A
(en)
|
2014-12-09 |
2021-08-06 |
艾伯维公司 |
Antibody drug conjugates with cell permeable BCL-XL inhibitors
|
EP3333191B1
(en)
|
2014-12-11 |
2020-09-09 |
Pierre Fabre Medicament |
Anti-c10orf54 antibodies and uses thereof
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
ES2870983T3
(en)
|
2014-12-19 |
2021-10-28 |
Univ Nantes |
Anti-IL-34 antibodies
|
WO2016106221A1
(en)
|
2014-12-22 |
2016-06-30 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
MX2017006864A
(en)
|
2014-12-23 |
2017-08-28 |
Genentech Inc |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers.
|
EP3240908A2
(en)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
JP2018504400A
(en)
|
2015-01-08 |
2018-02-15 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
LINGO-1 antagonist and use for treatment of demyelinating disorders
|
JP6659703B2
(en)
|
2015-01-09 |
2020-03-04 |
ジェネンテック, インコーポレイテッド |
Pyridazinone derivatives and their use in the treatment of cancer
|
JP6889661B2
(en)
|
2015-01-09 |
2021-06-18 |
ジェネンテック, インコーポレイテッド |
4,5-Dihydroimidazole derivative and its use as a histone dimethylase (KDM2B) inhibitor
|
JP6855379B2
(en)
|
2015-01-09 |
2021-04-07 |
ジェネンテック, インコーポレイテッド |
(Piperidin-3-yl) (naphthalene-2-yl) metanone derivatives and related compounds as inhibitors of histone demethylase KDM2B for the treatment of cancer
|
CN107530423B
(en)
|
2015-01-14 |
2022-04-05 |
布里格姆及妇女医院股份有限公司 |
Treatment of cancer with anti-LAP monoclonal antibodies
|
AU2016209032A1
(en)
|
2015-01-23 |
2017-08-10 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccination regimens
|
JP6709792B2
(en)
|
2015-01-29 |
2020-06-17 |
ジェネンテック, インコーポレイテッド |
Therapeutic compounds and uses thereof
|
CN107438593B
(en)
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
Therapeutic compounds and uses thereof
|
EP3250681B1
(en)
|
2015-01-31 |
2023-05-03 |
The Trustees of the University of Pennsylvania |
Compositions and methods for t cell delivery of therapeutic molecules
|
MA41598A
(en)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
PYRIDAZINE THERAPEUTIC COMPOUNDS AND THEIR USES
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
CN114504651A
(en)
|
2015-03-03 |
2022-05-17 |
科马布有限公司 |
Antibodies, uses and methods
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
US11155601B2
(en)
|
2015-03-06 |
2021-10-26 |
CSL Behring Lengnau AG |
Modified von Willebrand factor having improved half-life
|
IL296062A
(en)
|
2015-03-17 |
2022-10-01 |
Memorial Sloan Kettering Cancer Center |
Anti-muc16 antibodies and uses thereof
|
WO2016164480A1
(en)
|
2015-04-07 |
2016-10-13 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
MA42043A
(en)
|
2015-05-07 |
2018-03-14 |
Agenus Inc |
ANTI-OX40 ANTIBODIES AND METHODS OF USE THEREOF
|
IL255312B
(en)
|
2015-05-12 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer comprising a pd-l1 binding antagonist
|
FI3447075T3
(en)
|
2015-05-15 |
2023-11-07 |
Massachusetts Gen Hospital |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
US10174121B2
(en)
|
2015-05-29 |
2019-01-08 |
Abbvie, Inc. |
Anti-CD40 antibodies
|
EP3708681A1
(en)
|
2015-05-29 |
2020-09-16 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
EP3303394B1
(en)
|
2015-05-29 |
2020-04-08 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
TW201717935A
(en)
|
2015-06-03 |
2017-06-01 |
波士頓生醫公司 |
Compositions and methods for treating cancer
|
CN107810011A
(en)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
Use the method for anti-OX40 antibodies for treating cancer
|
EP3303397A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
TW201710286A
(en)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
Binding proteins against VEGF, PDGF, and/or their receptors
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
CN107922497B
(en)
|
2015-06-24 |
2022-04-12 |
詹森药业有限公司 |
anti-VISTA antibodies and fragments
|
DK3341376T3
(en)
|
2015-08-26 |
2021-03-29 |
Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio |
CONDENSED TRICYCLIC COMPOUNDS AS PROTEINKINASE INHIBITORS
|
PE20181275A1
(en)
|
2015-08-28 |
2018-08-03 |
Amunix Operating Inc |
CHEMERICAL POLYPEPTIDE ASSEMBLY AND METHODS FOR MAKING AND USING THE SAME
|
EA201890630A1
(en)
|
2015-09-01 |
2018-10-31 |
Эйдженус Инк. |
ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
|
RU2732591C2
(en)
|
2015-09-25 |
2020-09-21 |
Дженентек, Инк. |
Anti-tigit antibodies and methods of using
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
TW201720459A
(en)
|
2015-11-02 |
2017-06-16 |
妮翠斯製藥公司 |
Combination therapy of NTN1 neutralizing agent with drugs inhibiting epigenetic control
|
CA3003759A1
(en)
|
2015-11-03 |
2017-05-11 |
Merck Patent Gmbh |
Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
|
CN116217729A
(en)
|
2015-11-12 |
2023-06-06 |
思进公司 |
Glycan interaction compounds and methods of use
|
EP3380525B1
(en)
|
2015-11-25 |
2023-11-08 |
Immunogen, Inc. |
Pharmaceutical formulations and methods of use thereof
|
AU2016365117A1
(en)
|
2015-11-30 |
2018-05-31 |
Abbvie Biotherapeutics Inc. |
Anti-huLRRC15 antibody drug conjugates and methods for their use
|
EP3383909B1
(en)
|
2015-11-30 |
2020-06-17 |
AbbVie Inc. |
Anti-human lrrc15 antibody drug conjugates and methods for their use
|
KR20180100122A
(en)
|
2015-12-02 |
2018-09-07 |
주식회사 에스티사이언스 |
Antibodies specific for glycated BTLA (B- and T-lymphocyte weakening factor)
|
ES2861449T3
(en)
|
2015-12-02 |
2021-10-06 |
Stcube & Co Inc |
Antibodies and Molecules that Immunospecifically Bind to BTN1A1 and Their Therapeutic Uses
|
CA3007030A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
WO2017106647A1
(en)
|
2015-12-16 |
2017-06-22 |
Genentech, Inc. |
Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
|
EP3184544A1
(en)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein v inhibitors for use as coagulants
|
JP6962920B2
(en)
|
2015-12-31 |
2021-11-05 |
プロガストリン、エ、カンセル、エス、アー エル、エルProgastrine Et Cancers S.A R.L. |
Compositions and Methods for Detection and Treatment of Ovarian Cancer
|
CA3193501A1
(en)
|
2015-12-31 |
2017-07-06 |
Progastrine Et Cancers S.A R.L. |
Compositions and methods for detecting and treating gastric cancer
|
KR102197478B1
(en)
|
2015-12-31 |
2021-01-04 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
Compositions and methods for detecting and treating esophageal cancer
|
MX2018008175A
(en)
|
2015-12-31 |
2019-02-20 |
Syncerus S A R L |
Compositions and methods for assessing the risk of cancer occurrence.
|
CN108368179B
(en)
|
2016-01-08 |
2022-08-23 |
豪夫迈·罗氏有限公司 |
Methods of treating CEA positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD 3 bispecific antibodies
|
TWI756204B
(en)
|
2016-02-12 |
2022-03-01 |
比利時商楊森製藥公司 |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
AU2017225854B2
(en)
|
2016-02-29 |
2020-11-19 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
CA3011887A1
(en)
|
2016-03-14 |
2017-09-21 |
Stian FOSS |
Engineered immunoglobulins with altered fcrn binding
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
MA43715A
(en)
|
2016-03-17 |
2018-11-28 |
Numab Innovation Ag |
ANTI-TNF ANTIBODIES AND CORRESPONDING FUNCTIONAL FRAGMENTS
|
EP3430042B1
(en)
|
2016-03-17 |
2023-05-24 |
Numab Innovation AG |
Anti-tnfalpha-antibodies and functional fragments thereof
|
CA3016870A1
(en)
|
2016-03-17 |
2017-09-21 |
Numab Innovation Ag |
Anti-tnf.alpha.-antibodies and functional fragments thereof
|
RS61374B1
(en)
|
2016-03-17 |
2021-02-26 |
Tillotts Pharma Ag |
Anti-tnf alpha-antibodies and functional fragments thereof
|
PT3219727T
(en)
|
2016-03-17 |
2021-01-21 |
Tillotts Pharma Ag |
Anti-tnf alpha-antibodies and functional fragments thereof
|
CN108697799A
(en)
|
2016-03-22 |
2018-10-23 |
生态学有限公司 |
The application of anti-LGR5 monoclonal antibodies
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
BR112018069776A2
(en)
|
2016-03-29 |
2019-02-05 |
Janssen Biotech Inc |
psoriasis treatment with increased dosage range of anti-il-12 and / or anti-il-23 antibodies
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
CN109154027A
(en)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
For monitoring and the method for the treatment of cancer
|
WO2017180581A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
WO2017194568A1
(en)
|
2016-05-11 |
2017-11-16 |
Sanofi |
Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
|
SI3626273T1
(en)
|
2016-05-17 |
2021-04-30 |
Abbvie Biotherapeutics Inc. |
Anti-cmet antibody drug conjugates and methods for their use
|
CN109415441B
(en)
|
2016-05-24 |
2023-04-07 |
英斯梅德股份有限公司 |
Antibodies and methods of making same
|
WO2017205536A2
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
WO2017205538A1
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Pyrazolopyridine derivatives for the treatment of cancer
|
SG11201810023QA
(en)
|
2016-05-27 |
2018-12-28 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
BR112018074468A2
(en)
|
2016-05-27 |
2019-03-06 |
Abbvie Biotherapeutics Inc. |
anti-cd40 antibodies and their uses
|
EP3464362B1
(en)
|
2016-05-27 |
2020-12-09 |
AbbVie Biotherapeutics Inc. |
Anti-4-1bb antibodies and their uses
|
SI3462853T1
(en)
|
2016-06-03 |
2023-05-31 |
Regeneron Pharmaceuticals, Inc. |
Rodents expressing exogenous terminal deoxynucleotidyltransferase
|
CN109312407A
(en)
|
2016-06-08 |
2019-02-05 |
豪夫迈·罗氏有限公司 |
Diagnostic and therapeutic method for cancer
|
EP3458479B1
(en)
|
2016-06-08 |
2020-11-04 |
AbbVie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
PE20190510A1
(en)
|
2016-06-13 |
2019-04-10 |
I Mab |
ANTI-PD-L1 ANTIBODIES AND USES OF THE SAME
|
RU2022104399A
(en)
|
2016-06-14 |
2022-05-05 |
Ксенкор, Инк. |
BISPECIFIC ANTIBODIES-CHECKPOINT INHIBITORS
|
US11098107B2
(en)
|
2016-06-15 |
2021-08-24 |
Sutro Biopharma, Inc. |
Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
|
JP7237344B2
(en)
|
2016-06-15 |
2023-03-13 |
アイカーン スクール オブ メディシン アット マウント サイナイ |
Influenza virus hemagglutinin protein and uses thereof
|
CN116063545A
(en)
|
2016-06-28 |
2023-05-05 |
Xencor股份有限公司 |
Heterodimeric antibodies that bind somatostatin receptor 2
|
KR20190039937A
(en)
|
2016-07-08 |
2019-04-16 |
스태튼 바이오테크놀로지 비.브이. |
Anti-ApoC3 antibodies and methods of use thereof
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
CN109476748B
(en)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
Methods for treatment and diagnosis of cancer
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
PL3512547T3
(en)
|
2016-09-14 |
2021-03-08 |
Abbvie Biotherapeutics Inc. |
Anti-pd-1 antibodies
|
KR20190035790A
(en)
|
2016-09-19 |
2019-04-03 |
아이-맵 |
Anti-gm-csf antibodies and uses thereof
|
DK3515478T3
(en)
|
2016-09-21 |
2024-05-21 |
Nextcure Inc |
Antibodies to SIGLEC-15 and methods of use thereof
|
EP4360714A2
(en)
|
2016-09-21 |
2024-05-01 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
KR20190059305A
(en)
|
2016-09-30 |
2019-05-30 |
얀센 바이오테크 인코포레이티드 |
A safe and effective way to treat psoriasis with anti-IL23-specific antibodies
|
BR112019006706A2
(en)
|
2016-10-03 |
2019-06-25 |
Abbott Lab |
improved methods for assessing gfap status in patient samples
|
KR20190072528A
(en)
|
2016-10-06 |
2019-06-25 |
제넨테크, 인크. |
Treatment and Diagnosis Methods for Cancer
|
KR20230133934A
(en)
|
2016-10-11 |
2023-09-19 |
아게누스 인코포레이티드 |
Anti-lag-3 antibodies and methods of use thereof
|
EP3525829A1
(en)
|
2016-10-11 |
2019-08-21 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
KR102649972B1
(en)
|
2016-10-14 |
2024-03-22 |
젠코어 인코포레이티드 |
IL15/IL15Rα heterodimeric Fc-fusion protein
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
EP3534957A1
(en)
|
2016-11-02 |
2019-09-11 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and parp inhibitors
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
JP7045724B2
(en)
|
2016-11-07 |
2022-04-01 |
ニューラクル サイエンス カンパニー リミテッド |
Anti-Family 19, member A5 antibody with sequence similarity and its uses
|
AU2017362222A1
(en)
|
2016-11-16 |
2019-05-30 |
Janssen Biotech, Inc. |
Method of treating psoriasis with anti-IL-23 specific antibody
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
WO2018102427A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
CN110300599A
(en)
|
2016-12-07 |
2019-10-01 |
艾吉纳斯公司 |
Antibody and its application method
|
AU2017373944B2
(en)
|
2016-12-07 |
2022-02-03 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
KR102341926B1
(en)
|
2016-12-15 |
2021-12-23 |
애브비 바이오테라퓨틱스 인크. |
Anti-OX40 antibodies and uses thereof
|
US20190315852A1
(en)
|
2017-01-05 |
2019-10-17 |
Netris Pharma |
Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
|
TWI771361B
(en)
|
2017-01-20 |
2022-07-21 |
大陸商大有華夏生物醫藥集團有限公司 |
Monoclonal Antibody and Fragments of Human Programmed Death Receptor PD-1
|
MY188386A
(en)
|
2017-01-24 |
2021-12-07 |
I Mab Biopharma Us Ltd |
Anti-cd73 antibodies and uses thereof
|
CA3051484A1
(en)
|
2017-01-27 |
2018-08-02 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
CN110234351A
(en)
|
2017-01-30 |
2019-09-13 |
詹森生物科技公司 |
For treating the anti-TNF antibodies, composition and method of activity psoriatic arthritis
|
JP2020506947A
(en)
|
2017-02-07 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
Anti-TNF antibodies, compositions and methods for treating active ankylosing spondylitis
|
TW201837467A
(en)
|
2017-03-01 |
2018-10-16 |
美商建南德克公司 |
Diagnostic and therapeutic methods for cancer
|
JP2020510671A
(en)
|
2017-03-03 |
2020-04-09 |
シアトル ジェネティックス, インコーポレイテッド |
Glycan interacting compounds and methods of use
|
MA47775A
(en)
|
2017-03-14 |
2020-01-22 |
Amgen Inc |
CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE
|
TWI808963B
(en)
|
2017-03-22 |
2023-07-21 |
法商賽諾菲公司 |
Treatment of lupus using humanized anti-cxcr5 antibodies
|
CA3052513A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
SG11201908888VA
(en)
|
2017-03-30 |
2019-10-30 |
Progastrine Et Cancers S A R L |
Compositions and methods for treating lung cancer
|
KR102317805B1
(en)
|
2017-03-30 |
2021-10-27 |
이씨에스-프로가스트린 에스에이 |
Compositions and methods for detecting prostate cancer
|
WO2018187706A2
(en)
|
2017-04-07 |
2018-10-11 |
Icahn School Of Medicine At Mount Sinai |
Anti-influenza b virus neuraminidase antibodies and uses thereof
|
MX2019012223A
(en)
|
2017-04-13 |
2019-12-09 |
Agenus Inc |
Anti-cd137 antibodies and methods of use thereof.
|
BR112019021411A2
(en)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
methods to treat or slow the progression of cancer and to improve function, uses of an immunoconjugate, an agonist, an antagonist, compositions, kit and invention
|
CN110546513A
(en)
|
2017-04-15 |
2019-12-06 |
雅培实验室 |
Methods for using early biomarkers to aid in hyperacute diagnosis and determination of traumatic brain injury in human subjects
|
AU2018255938A1
(en)
|
2017-04-21 |
2019-10-31 |
Staten Biotechnology B.V. |
Anti-ApoC3 antibodies and methods of use thereof
|
EP3615052B1
(en)
|
2017-04-27 |
2023-01-25 |
The University of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
EP3635407A1
(en)
|
2017-04-28 |
2020-04-15 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
EP3618863B1
(en)
|
2017-05-01 |
2023-07-26 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
JOP20190256A1
(en)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
Newcastle disease viruses and uses thereof
|
EP3624846A1
(en)
|
2017-05-16 |
2020-03-25 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
WO2018213424A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
US10866251B2
(en)
|
2017-05-25 |
2020-12-15 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
BR112019025387A2
(en)
|
2017-05-30 |
2020-07-07 |
Abbott Laboratories |
methods to assist in the diagnosis and evaluation of a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
|
KR20200024158A
(en)
|
2017-05-31 |
2020-03-06 |
주식회사 에스티큐브앤컴퍼니 |
How to treat cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
AU2018277838A1
(en)
|
2017-05-31 |
2019-12-19 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
JP2020522562A
(en)
|
2017-06-06 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Methods of treating cancer with antibodies and molecules that bind to BTN1A1 or BTN1A1 ligand
|
CA3067603A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
PE20200616A1
(en)
|
2017-07-14 |
2020-03-11 |
Pfizer |
ANTIBODIES AGAINST MADCAM
|
TWI823859B
(en)
|
2017-07-21 |
2023-12-01 |
美商建南德克公司 |
Therapeutic and diagnostic methods for cancer
|
CA3071105A1
(en)
|
2017-07-27 |
2019-01-31 |
Nomocan Pharmaceuticals Llc |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
AU2018316343A1
(en)
|
2017-08-11 |
2020-02-13 |
Genentech, Inc. |
Anti-CD8 antibodies and uses thereof
|
AU2018330180A1
(en)
|
2017-09-07 |
2020-03-19 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
AU2018329925A1
(en)
|
2017-09-08 |
2020-03-05 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
TW201922780A
(en)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
|
US11123330B2
(en)
|
2017-09-28 |
2021-09-21 |
The Governing Council Of The University Of Toronto |
Methods and compositions for inhibiting mutant EGFR signaling
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
EP3710001A4
(en)
|
2017-10-27 |
2021-07-14 |
University Of Virginia Patent Foundation |
Compounds and methods for regulating, limiting, or inhibiting avil expression
|
WO2019089594A1
(en)
|
2017-10-31 |
2019-05-09 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and cytarabine
|
CN111315772A
(en)
|
2017-10-31 |
2020-06-19 |
斯塔顿生物技术有限公司 |
anti-APOC 3 antibodies and methods of use thereof
|
EP3707510B1
(en)
|
2017-11-06 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
AU2018368338A1
(en)
|
2017-11-16 |
2020-04-09 |
Amgen Inc. |
Autoinjector with stall and end point detection
|
US11401345B2
(en)
|
2017-11-27 |
2022-08-02 |
Purdue Pharma L.P. |
Humanized antibodies targeting human tissue factor
|
PL3720879T3
(en)
|
2017-12-05 |
2022-09-12 |
Progastrine Et Cancers S.À R.L. |
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
|
JP7344801B2
(en)
|
2017-12-09 |
2023-09-14 |
アボット・ラボラトリーズ |
Glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) Methods to assist in diagnosis and assessment of injuries sustained or potential injuries
|
JP7379165B2
(en)
|
2017-12-09 |
2023-11-14 |
アボット・ラボラトリーズ |
Methods for aiding in diagnosing and assessing traumatic brain injury in human subjects using a combination of GFAP and UCH-L1
|
CA3086199A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
TW201940881A
(en)
|
2018-01-26 |
2019-10-16 |
瑞士商Ecs前胃泌激素公司 |
Combining progastrin detection with other cancer biomarkers in cancer diagnosis
|
CA3092108A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
TW202000699A
(en)
|
2018-02-27 |
2020-01-01 |
瑞士商Ecs前胃泌激素公司 |
Progastrin as a biomarker for immunotherapy
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
MX2020009265A
(en)
|
2018-03-05 |
2020-10-01 |
Janssen Biotech Inc |
Methods of treating crohn's disease with anti-il23 specific antibody.
|
BR112020017701A2
(en)
|
2018-03-12 |
2020-12-29 |
Zoetis Services Llc |
ANTI-NGF ANTIBODIES AND METHODS OF THE SAME
|
MA52186A
(en)
|
2018-03-26 |
2021-02-17 |
Amgen Inc |
TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE
|
PE20201343A1
(en)
|
2018-04-02 |
2020-11-25 |
Bristol Myers Squibb Co |
ANTI-TREM-1 ANTIBODIES AND USES OF THEM
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
CN112004558A
(en)
|
2018-04-12 |
2020-11-27 |
米迪亚制药有限责任公司 |
LGALS3BP antibody-drug-conjugate and its use for the treatment of cancer
|
EP3781599A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
WO2019207159A1
(en)
|
2018-04-27 |
2019-10-31 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
AU2019265888A1
(en)
|
2018-05-10 |
2020-11-26 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
EP3790587A4
(en)
|
2018-05-11 |
2022-01-26 |
Janssen Biotech, Inc. |
Methods of treating depression using il-23 antibodies
|
WO2019222130A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and flt3 inhibitors
|
WO2019226514A2
(en)
|
2018-05-21 |
2019-11-28 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
CN113286616A
(en)
|
2018-05-23 |
2021-08-20 |
Adc治疗有限公司 |
Molecular adjuvant
|
CN112805381A
(en)
|
2018-06-21 |
2021-05-14 |
优曼尼蒂治疗公司 |
Compositions and methods for treating and preventing neurological disorders
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
WO2020003210A1
(en)
|
2018-06-29 |
2020-01-02 |
Kangwon National University University-Industry Cooperation Foundation |
Anti-l1cam antibodies and uses thereof
|
US10976561B2
(en)
|
2018-06-29 |
2021-04-13 |
Viavi Solutions Inc. |
Optical devices with azimuthal modulator layer
|
JP2021530697A
(en)
|
2018-07-18 |
2021-11-11 |
ヤンセン バイオテツク,インコーポレーテツド |
Sustained response predictor after treatment with anti-IL23 specific antibody
|
MX2021000558A
(en)
|
2018-07-18 |
2021-04-13 |
Genentech Inc |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent.
|
CN112740043A
(en)
|
2018-07-20 |
2021-04-30 |
皮埃尔法布雷医药公司 |
VISTA receptor
|
WO2020028909A1
(en)
|
2018-08-03 |
2020-02-06 |
Brown University |
Oral formulations with increased uptake
|
WO2020051099A1
(en)
|
2018-09-03 |
2020-03-12 |
Genentech, Inc. |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
CA3160103A1
(en)
|
2018-09-24 |
2020-04-02 |
Janssen Biotech, Inc. |
Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
|
WO2020072821A2
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
CN112969503A
(en)
|
2018-10-03 |
2021-06-15 |
斯塔滕生物技术有限公司 |
Antibodies specific for human and cynomolgus macaques APOC3 and methods of use thereof
|
GB201816554D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
GB201816553D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
TW202035445A
(en)
|
2018-10-10 |
2020-10-01 |
美商帝洛斯療法股份有限公司 |
Anti-lap antibody variants and uses thereof
|
US20210340277A1
(en)
|
2018-10-11 |
2021-11-04 |
The Scripps Research Institute |
Antibody compounds with reactive arginine and related antibody drug conjugates
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
EP3883610A4
(en)
|
2018-11-20 |
2022-11-02 |
Cornell University |
Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
|
AU2019383017A1
(en)
|
2018-11-20 |
2021-06-03 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
US20220026445A1
(en)
|
2018-12-07 |
2022-01-27 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
WO2020127376A2
(en)
|
2018-12-17 |
2020-06-25 |
Alligator Bioscience Ab |
Novel polypeptides
|
US20220064325A1
(en)
|
2018-12-17 |
2022-03-03 |
Alligator Bioscience Ab |
Novel polypeptides
|
EP3897722A4
(en)
|
2018-12-18 |
2022-09-14 |
Janssen Biotech, Inc. |
Safe and effective method of treating lupus with anti-il12/il23 antibody
|
JP2022515197A
(en)
|
2018-12-19 |
2022-02-17 |
アレイ バイオファーマ インコーポレイテッド |
7-((3,5-dimethoxyphenyl) amino) quinoxaline derivative as an FGFR inhibitor for treating cancer
|
EP3898626A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
WO2020136145A2
(en)
|
2018-12-26 |
2020-07-02 |
Innate Pharma |
Leucocyte immunoglobulin-like receptor neutralizing antibodies
|
WO2020138487A1
(en)
|
2018-12-28 |
2020-07-02 |
協和キリン株式会社 |
BISPECIFIC ANTIBODY BINDING TO TfR
|
CA3126654A1
(en)
|
2019-01-15 |
2020-07-23 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
MX2021008871A
(en)
|
2019-01-23 |
2021-08-19 |
Janssen Biotech Inc |
Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis.
|
AU2019427766A1
(en)
|
2019-01-30 |
2021-09-16 |
Nomocan Pharmaceuticals Llc |
Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
|
WO2020163589A1
(en)
|
2019-02-08 |
2020-08-13 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
WO2020168555A1
(en)
|
2019-02-22 |
2020-08-27 |
武汉友芝友生物制药有限公司 |
Cd3 antigen binding fragment and application thereof
|
MA55080A
(en)
|
2019-02-26 |
2022-01-05 |
Inspirna Inc |
HIGH AFFINITY ANTI-MERTK ANTIBODIES AND ASSOCIATED USES
|
CN113677994A
(en)
|
2019-02-27 |
2021-11-19 |
外延轴治疗股份有限公司 |
Methods and agents for assessing T cell function and predicting response to therapy
|
JP2022521773A
(en)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
Dosing for treatment with anti-TIGIT antibody and anti-CD20 antibody or anti-CD38 antibody
|
MX2021010390A
(en)
|
2019-03-01 |
2021-11-17 |
Xencor Inc |
Heterodimeric antibodies that bind enpp3 and cd3.
|
EP3938391A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
JP2022525179A
(en)
|
2019-03-14 |
2022-05-11 |
ヤンセン バイオテツク,インコーポレーテツド |
Production method for producing anti-TNF antibody composition
|
CA3133395A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-il12/il23 antibody compositions
|
US20220153829A1
(en)
|
2019-03-14 |
2022-05-19 |
Janssen Biotech, Inc. |
Methods for Producing Anti-TNF Antibody Compositions
|
KR102588292B1
(en)
|
2019-03-15 |
2023-10-11 |
카티전 테라퓨틱스, 인코포레이티드 |
anti-BCMA chimeric antigen receptor
|
CN113853385A
(en)
|
2019-03-18 |
2021-12-28 |
詹森生物科技公司 |
Methods of treating psoriasis in pediatric subjects with anti-IL 12/IL23 antibodies
|
WO2020198413A1
(en)
|
2019-03-27 |
2020-10-01 |
The Trustees Of The University Of Pennsylvania |
Tn-muc1 chimeric antigen receptor (car) t cell therapy
|
EP3947442A2
(en)
|
2019-03-28 |
2022-02-09 |
Danisco US Inc. |
Engineered antibodies
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
WO2020226986A2
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
BR112021023295A2
(en)
|
2019-05-23 |
2022-02-08 |
Janssen Biotech Inc |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf-alpha
|
KR20220030952A
(en)
|
2019-06-03 |
2022-03-11 |
얀센 바이오테크 인코포레이티드 |
Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
WO2020245676A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
WO2020252043A1
(en)
|
2019-06-10 |
2020-12-17 |
Sutro Biopharma, Inc. |
5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF
|
WO2020257235A1
(en)
|
2019-06-17 |
2020-12-24 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
|
CN112300279A
(en)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
Methods and compositions directed to anti-CD 73 antibodies and variants
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
KR20220053007A
(en)
|
2019-08-30 |
2022-04-28 |
아게누스 인코포레이티드 |
Anti-CD96 antibodies and methods of use thereof
|
WO2021043206A1
(en)
|
2019-09-03 |
2021-03-11 |
百奥泰生物制药股份有限公司 |
Anti-tigit immunosuppressant and application thereof
|
MX2022002738A
(en)
|
2019-09-04 |
2022-06-27 |
Genentech Inc |
Cd8 binding agents and uses thereof.
|
EP4041767A1
(en)
|
2019-09-26 |
2022-08-17 |
StCube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
BR112022005583A2
(en)
|
2019-09-26 |
2022-09-20 |
Amgen Inc |
METHODS FOR PRODUCTION OF ANTIBODY COMPOSITIONS
|
AU2020351734A1
(en)
|
2019-09-27 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
|
KR20220088438A
(en)
|
2019-10-09 |
2022-06-27 |
주식회사 에스티큐브앤컴퍼니 |
Antibodies specific for glycosylated LAG3 and methods of use thereof
|
WO2021083949A1
(en)
|
2019-10-29 |
2021-05-06 |
F. Hoffmann-La Roche Ag |
Bifunctional compounds for the treatment of cancer
|
KR20220092580A
(en)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
Diagnosis and treatment methods for the treatment of blood cancer
|
KR20220101138A
(en)
|
2019-11-13 |
2022-07-19 |
제넨테크, 인크. |
Therapeutic compounds and methods of use
|
EP3825330A1
(en)
|
2019-11-19 |
2021-05-26 |
International-Drug-Development-Biotech |
Anti-cd117 antibodies and methods of use thereof
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
AU2020403145A1
(en)
|
2019-12-13 |
2022-07-07 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
WO2021127404A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
AU2021205893A1
(en)
|
2020-01-08 |
2022-06-23 |
Synthis Therapeutics, Inc. |
ALK5 inhibitor conjugates and uses thereof
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
EP4114860A1
(en)
|
2020-03-06 |
2023-01-11 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
WO2021177438A1
(en)
|
2020-03-06 |
2021-09-10 |
第一三共株式会社 |
Antibody-drug conjugate including novel cyclic dinucleotide derivative
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
IL296241A
(en)
|
2020-03-10 |
2022-11-01 |
Massachusetts Inst Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
CN115362171A
(en)
|
2020-03-31 |
2022-11-18 |
百奥泰生物制药股份有限公司 |
Antibody for treating coronavirus, fusion protein and application thereof
|
CN115698717A
(en)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
Methods of treatment and diagnosis of cancer
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
EP4143234A1
(en)
|
2020-04-26 |
2023-03-08 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Modified immunoglobulins
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
EP3915641A1
(en)
|
2020-05-27 |
2021-12-01 |
International-Drug-Development-Biotech |
Anti-cd5 antibodies and methods of use thereof
|
EP3915576A1
(en)
|
2020-05-28 |
2021-12-01 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Chimeric antigen receptors specific for p95her2 and uses thereof
|
WO2021247908A1
(en)
|
2020-06-03 |
2021-12-09 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
US20230273126A1
(en)
|
2020-06-04 |
2023-08-31 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
AU2021293038A1
(en)
|
2020-06-16 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating triple-negative breast cancer
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
US20230235408A1
(en)
|
2020-06-30 |
2023-07-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
|
US20230266322A1
(en)
|
2020-06-30 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
|
EP3939999A1
(en)
|
2020-07-14 |
2022-01-19 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
|
EP4185322A2
(en)
|
2020-07-24 |
2023-05-31 |
Amgen Inc. |
Immunogens derived from sars-cov2 spike protein
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
CN116568824A
(en)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
Method for diagnosing and treating lymphoma
|
EP4193149A1
(en)
|
2020-08-04 |
2023-06-14 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
CN114057877A
(en)
|
2020-08-07 |
2022-02-18 |
百奥泰生物制药股份有限公司 |
anti-PD-L1 antibody and application thereof
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
EP4210832A1
(en)
|
2020-09-14 |
2023-07-19 |
Vor Biopharma, Inc. |
Chimeric antigen receptors for treatment of cancer
|
WO2022066805A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
CA3197930A1
(en)
|
2020-10-15 |
2022-04-21 |
Amgen Inc. |
Relative unpaired glycans in antibody production methods
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
CN114437227A
(en)
|
2020-11-06 |
2022-05-06 |
百奥泰生物制药股份有限公司 |
Bispecific antibodies and uses thereof
|
WO2022103983A2
(en)
|
2020-11-11 |
2022-05-19 |
Sutro Biopharma, Inc. |
Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
|
WO2022100694A1
(en)
|
2020-11-12 |
2022-05-19 |
迈威(上海)生物科技股份有限公司 |
Antibody and preparation method therefor
|
WO2022104697A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Bliss Biopharmaceutical (Hangzhou) Co., Ltd. |
Modified egfr antibody with reduced affinity
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2022119841A1
(en)
|
2020-12-01 |
2022-06-09 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
EP4271998A1
(en)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
UY39610A
(en)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
ANTI-EGFR ANTIBODY-DRUG CONJUGATES
|
WO2022161314A1
(en)
|
2021-01-27 |
2022-08-04 |
信达生物制药(苏州)有限公司 |
Single-domain antibody against cd16a and use thereof
|
TW202241454A
(en)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
Novel method for producing antibody-immunostimulator conjugate
|
JP2024506339A
(en)
|
2021-02-12 |
2024-02-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
WO2022187591A1
(en)
|
2021-03-05 |
2022-09-09 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
AU2022232375A1
(en)
|
2021-03-09 |
2023-09-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
US20220298236A1
(en)
|
2021-03-12 |
2022-09-22 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
|
JP2024510588A
(en)
|
2021-03-12 |
2024-03-08 |
ヤンセン バイオテツク,インコーポレーテツド |
Method of treating psoriatic arthritis patients with inadequate response to TNF therapy with anti-IL23-specific antibodies
|
KR20230157983A
(en)
|
2021-03-12 |
2023-11-17 |
다이이찌 산쿄 가부시키가이샤 |
Method for manufacturing sugar chains and medicines containing sugar chains
|
JP2024514530A
(en)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Antibodies against truncated CDCP1 and uses thereof
|
TW202307007A
(en)
|
2021-05-04 |
2023-02-16 |
美商再生元醫藥公司 |
Multispecific fgf21 receptor agonists and their uses
|
WO2022245920A1
(en)
|
2021-05-18 |
2022-11-24 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
KR20240026948A
(en)
|
2021-05-25 |
2024-02-29 |
에라스카, 아이엔씨. |
Sulfur-containing heteroaromatic tricyclic KRAS inhibitor
|
AU2022289365A1
(en)
|
2021-06-07 |
2023-12-14 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
BR112023026199A2
(en)
|
2021-06-14 |
2024-03-05 |
Abbott Lab |
METHODS FOR DIAGNOSING OR ASSISTING IN THE DIAGNOSIS OF BRAIN INJURY CAUSED BY ACOUSTIC ENERGY, ELECTROMAGNETIC ENERGY, OVERPRESSURIZATION WAVE AND/OR GUST OF WIND
|
IL309349A
(en)
|
2021-06-14 |
2024-02-01 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
CN117957251A
(en)
|
2021-07-09 |
2024-04-30 |
詹森生物科技公司 |
Method for preparing anti-TNF antibody compositions
|
US20230040065A1
(en)
|
2021-07-09 |
2023-02-09 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-TNF Antibody Compositions
|
WO2023281466A1
(en)
|
2021-07-09 |
2023-01-12 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-il12/il23 antibody compositions
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
WO2023010118A1
(en)
|
2021-07-29 |
2023-02-02 |
Vor Biopharma Inc. |
Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
|
AU2022324456A1
(en)
|
2021-08-05 |
2024-02-15 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
TW202321261A
(en)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
Selective kras inhibitors
|
EP4388008A1
(en)
|
2021-08-16 |
2024-06-26 |
Hemogenyx Pharmaceuticals Llc |
Anti-flt3 antibodies, cars, car t cells and methods of use
|
WO2023023489A2
(en)
|
2021-08-17 |
2023-02-23 |
Hemogenyx Pharmaceuticals Llc |
Bispecific anti-flt3/cd3 antibodies and methods of use
|
WO2023034777A1
(en)
|
2021-08-31 |
2023-03-09 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
CA3230933A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
WO2023034569A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
CN115894689A
(en)
|
2021-09-30 |
2023-04-04 |
百奥泰生物制药股份有限公司 |
anti-B7-H3 antibodies and uses thereof
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
AU2022361382A1
(en)
|
2021-10-05 |
2024-03-28 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
WO2023073615A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
WO2023079058A1
(en)
|
2021-11-05 |
2023-05-11 |
Yokogawa Insilico Biotechnology Gmbh |
Cell culture with reduced production of lactate
|
US20230151087A1
(en)
|
2021-11-15 |
2023-05-18 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
WO2023095000A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
TW202332429A
(en)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
Therapeutic compounds and methods of use
|
US20230203062A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
CA3240822A1
(en)
|
2021-12-17 |
2023-06-22 |
Tony Lee |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
AU2022424002A1
(en)
|
2021-12-29 |
2024-06-13 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023164487A1
(en)
|
2022-02-22 |
2023-08-31 |
Brown University |
Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
|
EP4245772A1
(en)
|
2022-03-18 |
2023-09-20 |
Netris Pharma |
Anti-netrin-1 antibody to treat liver inflammation
|
EP4249509A1
(en)
|
2022-03-22 |
2023-09-27 |
Netris Pharma |
Anti-netrin-1 antibody against arthritis-associated pain
|
WO2023186968A1
(en)
|
2022-03-29 |
2023-10-05 |
Netris Pharma |
Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
|
EP4253418A1
(en)
|
2022-03-29 |
2023-10-04 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
|
US20230312703A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis with IL-23 Specific Antibody
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20230374122A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024006272A1
(en)
|
2022-06-27 |
2024-01-04 |
Sutro Biopharma, Inc. |
β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024015229A1
(en)
|
2022-07-15 |
2024-01-18 |
Sutro Biopharma, Inc. |
Protease/enzyme cleavable linker-payloads and protein conjugates
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
KR20240066490A
(en)
|
2022-10-28 |
2024-05-16 |
주식회사 휴온스랩 |
Antibody-Cytokine fusion protein and the uses thereof
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
US20240199734A1
(en)
|
2022-11-22 |
2024-06-20 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2024118866A1
(en)
|
2022-12-01 |
2024-06-06 |
Modernatx, Inc. |
Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
|